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Adherence is the first and one of the most important steps of bacterial 
pathogenesis. Natural derived components that inhibit the adherence of 
pathogens to the surface of epithelial cells have received considered interest. 
The goal of this research was to assess the anti-adherence activity of mannan 
oligosaccharides (MOS), pectic oligosaccharides (POS) and cranberry high 
molecular weight component (HMW) against Campylobacter jejuni and 
Campylobacter coli. First the anti-adherence activity of MOS and their purified 
fraction (pMOS) was tested against three strains of C. jejuni and two strains of C. 
coli. Results shown significant reductions in adherence (up to 70%) of all C. jejuni 
strains and for C. coli ATCC 43485 in presence of MOS or pMOS (50 mg/mL). 
The mannan oligosaccharide fraction appear to be the responsible for the anti-
adherence activity of MOS. Adherence inhibition (up to 70%) was also observed!
in presence of HMW at the highest concentration of 5 mg/mL of all the strains 
except for C. coli ATCC BAA-1061. Additionally, a blend of MOS-HMW did not 
shown additive effect to inhibit the adherence of all five Campylobacter strains. 
POS was not effective to inhibit the adherence of any of the strains tested in this 
study.  Invasion inhibition was not observed in the presence of any of the 
components tested. These results show that naturally derived molecules as MOS 
and HMW can be used for animal production to reduce pathogens colonization 
and prevent the onset of human infection. 
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Preface 
 
 
This thesis is compromised of five chapters. Chapter 1 provides a review of the 
current literature on the anti-adherence effect of different non-digestible 
oligosaccharides and plant extracts. Chapter 2 provides a review of the uses of 
mannan oligosaccharides as animal feed supplement. Chapter 3 describes a 
study on the effect of Mannan oligosaccharides and Cranberry high molecular 
weight component on the adherence of Campylobacter jejuni and Campylobacter 
coli in HEp-2 cells. Chapter 4 describes the results of testing pectin 
oligosaccharides as anti-adherence agents against Campylobacter jejuni and 
Campylobacter coli to HEp-2 cells. Finally, Chapter 5 provides a conclusion 
session that summarizes the major research findings presented within this thesis. 
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Introduction 47!
Non-digestible oligosaccharides (NDO) have received much recent 48!
research and commercial attention due to their important functional, 49!
physiological, and biological properties. In particular, some NDOs have the ability 50!
to modulate the intestinal microbiota by enriching for health-promoting bacteria. 51!
In addition, NDO may also interfere with the ability of enteric pathogens to 52!
colonize the intestinal tract (Paeschke & Aimutis, 2011). 53!
  Many commercial NDO are either found naturally or are derived from 54!
plant materials. Others are obtained from microbial sources, including fungi.  In 55!
addition, shellfish and milk can also serve as a source of NDO. 56!
Galactooligosaccharides (GOS), fructooligosaccharides (FOS) and inulin are well 57!
studied NDOs that has been recognized for their prebiotic properties. Anew class 58!
of NDOs that have gained interest in the past years are derived from plant cell 59!
wall polysaccharides. Similar hydrolysis processes are used to obtain 60!
oligosaccharides from these sources. For example, arabinogalacto- 61!
oligosaccharides can be made from soybeans and sugar beets, 62!
rhamnogalacturono-oligosaccharides from apple, mannan-oligosaccharide from 63!
yeast, xylo-oligosaccharides from bamboo shoots, pectic oligosaccharides from 64!
orange pectin (Mussatto & Mancilha, 2007; Voragen, 1998). 65!
Several of these oligosaccharides are derived from waste materials 66!
resulting from food processing and other of manufacturing industries.  There is 67!
much interest in these products due to their low raw material cost and potential 68!
bioactive properties. This interest has led to development of new technologies for 69!
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extraction and purification of NDOs, as well as studies to analyze their structural 70!
and function properties. 71!
In this review, the composition and structure of several important NDOs 72!
and their biological properties will be presented. The primary focus will be on the 73!
ability of NDO to reduce adherence of enteric pathogens, especially 74!
Campylobacter, one of the leading causes of gastroenteritis in the U.S. 75!
 76!
Physical-chemical properties of non-digestible oligosaccharides 77!
Non-digestible oligosaccharides (NDOs) are defined as carbohydrates that 78!
are not digested (or minimally digested) in the stomach or small intestine and 79!
arrive in the large intestine mostly intact, where they might then be utilized by gut 80!
microbiota (Paeschke & Aimutis, 2011). This concept was based, in part, on the 81!
observation that the anomeric carbon atom (C1 to C2) of monosaccharide units 82!
of some dietary oligosaccharides has a configuration that makes their osidic 83!
bounds (also called glycosidic linkages) non-digestible to the hydrolytic activity of 84!
the human digestive enzymes (Mussatto & Mancilha, 2007; Roberfroid & Slavin, 85!
2000). NDOs are made from one, two or even three different types of 86!
monosaccharides (Crittenden & Playner, 1996). They are generally low 87!
molecular weight carbohydrates, containing sugar moieties with degrees of 88!
polymerization (DP) between 3 and 10. (Patel & Goyal, 2011;Weijers et al., 2008) 89!
and water soluble usually between 0.3-0.6 times as sweet sucrose. 90!
NDOs are widely found in nature and are common constituents of many 91!
foods such as milk, honey, fruits and vegetables (i.e. onion, Jerusalem artichoke, 92!
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chicory, leek, garlic, artichoke, banana, rye, barley) (Crittenden & Playner, 1996; 93!
Mussatto & Mancilha, 2007). These naturally-derived components are produced 94!
by hydrolyzing polysaccharides or by enzymatic and chemical synthesis from 95!
disaccharide substrates (Mussatto & Mancilha, 2007; Sako et al., 1999) (Table 96!
2). 97!
NDOs have been associated with many health benefits, including positive 98!
effects on fermentation, mineral absorption, barrier function, fat metabolism, 99!
glycemic and insulin responses (Meyer, 2004; Nauta & Garssen, 2013). Hence, 100!
they have been introduced as functional food ingredients (Mussatto & Mancilha, 101!
2007; Van Loo et al., 1999).  102!
 103!
The Campylobacter problem 104!
Campylobacter infection is a leading cause of human bacterial 105!
gastroenteritis in the United States, with more than 1.3 million campylobacteriosis 106!
cases reported in 2012 (CDC, 2013a).  Poultry has been identified as a major 107!
reservoir for this pathogen, and contaminated broiler chicken meat is believed to 108!
be responsible for 50 - 70% of the human Campylobacter cases (EFSA, 2010; 109!
Hermans et al., 2011). Indeed, chickens are commonly colonized by 110!
Campylobacter jejuni, with prevalence rates of 60-80% (EFSA, 2010).  Therefore, 111!
strategies to prevent Campylobacter colonization in chicken are a high priority. 112!
 113!
 114!
 115!
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Epidemiology 116!
Campylobacter spp. are commonly found as commensals in the 117!
gastrointestinal tract of wild or domesticated cattle, sheep, swine, goat, dogs, 118!
cats, and all classes of poultry; (Lee & Newell, 2006; Stanley & Jones, 2003). C. 119!
jejuni is predominantly associated with poultry (EFSA, 2004; FAO/WHO, 2009; 120!
Tauxe et al.,1992) and C. coli is found at higher prevalence in pigs (EFSA, 2004; 121!
Nielsen et al., 1997; Rosef et al., 1983). The handling and consumption of poultry 122!
meat is considered a significant risk for human infection (Corry & Atabay, 2001; 123!
Ganan et al., 2009). 124!
The most important foodborne species of Campylobacter are 125!
Campylobacter jejuni and Campylobacter coli.  Together, they account for over 126!
95% of Campylobacter infections in humans (Park, 2002). Surveys have 127!
suggested that in the U.S., nearly 70% of chicken carcasses processed on-farm 128!
are contaminated with Campylobacter (Timble et al., 2013).  These authors 129!
reported that in the slaughter facility this number increased to 82%. The 130!
Foodborne Disease Active Surveillance Network (FoodNet) found a 30% decline 131!
in the rates of infection in 2009 for Campylobacter compared with previous years.  132!
However, low level of contamination is a public health risk, since the reported 133!
infectious dose for this pathogen is less than 500 CFU (Black et al., 1988; Park, 134!
2002).   135!
Moreover, it is generally assumed that C. jejuni and C. coli do not multiply 136!
during slaughter, post-processing, transport and refrigeration storage of chicken 137!
products, since they require high growth temperature of around 42°C 138!
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!
(FAO/WHO, 2009). However, Campylobacter spp. can persist for long times in 139!
chilled and frozen products. Proper cooking is sufficient to inactivate 140!
Campylobacter as they are sensitive to heat (FAO/WHO, 2009; ICMSF, 1996). 141!
 142!
Campylobacteriosis 143!
In many industrialized nations, Campylobacter jejuni is the most frequently 144!
identified pathogen associated with acute diarrheal disease (Acheson & Allos, 145!
2001). Campylobacter infections usually involve sporadic cases, or as part of 146!
small, family-related outbreaks (FAO/WHO, 2009). The infection due to 147!
Campylobacter is called campylobacteriosis and are most prevalence in children, 148!
elderly people and patients with compromised immune system (Wassenaar & 149!
Blaser, 1999; Young et al., 2007). Any individual who has consumed the 150!
organism from contaminated food or water is at risk of develop the disease 151!
(Altekruse et al., 1999). However, campylobacteriosis is a self-limited disease, 152!
and most patients recover almost completely after 1 week (Dasti et al., 2010). 153!
In developing countries, Campylobacter species are an important cause of 154!
childhood morbidity caused by watery diarrhea predominantly (Acheson & Allos, 155!
2001). In developed countries, campylobacteriosis manifests as bloody diarrhea 156!
with mucus, and is usually self-limiting (Young et al., 2007). Although 14 species 157!
of Campylobacter have been identified, in the United States, more than 99% of 158!
reported infections with Campylobacter are with C. jejuni (Buzby et al., 1997; 159!
Friedman et al., 2000). Approximately 0.1% of C. jejuni cases are associated with 160!
serious ascending motor neuron paralytic disease Guillain-Barré syndrome 161!
! 7!
!
(Mandrell et al., 2005; Nachamkin et al., 1998). Studies have reported that 20% 162!
to 40% of patients with Guillain-Barré syndrome (GBS) have evidence of recent 163!
Campylobacter jejuni infection (Buzby et al., 1997; CDC, 2013b), in the 1-3 164!
weeks prior to the onset of neurologic symptoms (Rees et al., 1995).  Ang et al., 165!
2004 have suggested that C. jejuni probably triggers the GBS through molecular 166!
mimicry between core lipooligosaccharides (LOS) in the bacterial cell wall and 167!
gangliosides in human peripheral nerve tissue as a consequence cause the 168!
paralysis. 169!
Worldwide, the economic loss due to C. jejuni infection has been 170!
estimated to be in excess of US$ 2 billion per year (CDC, 2013b). Adding to the 171!
human and economic costs of C. jejuni are the chronic sequelae associated with 172!
this infection (Altekruse et al., 1999). In 2012, the Foodborne Diseases Active 173!
Surveillance Network (FoodNet) estimated the incidence to be 14.3 cases per 174!
100,000 populations. An estimated 1.3 million persons are affected each year 175!
(CDC, 2013b). 176!
Campylobacter and antibiotics 177!
Antibiotics are commonly given to chickens to promote growth by 178!
increasing weight gain, improving feed efficiencies, reducing mortality, and 179!
inhibiting pathogens colonization (Gaskins el al., 2002; Phillips et al., 2004).  180!
However, the emergence of antibiotic resistant Campylobacter strains has 181!
significantly increased in the recent years (Rautelin et al., 1991; White et al., 182!
2002). In 2006, the European Union banned the use of antibiotics in animal feed. 183!
! 8!
!
Hence, alternative approaches to reduce Campylobacter colonization in livestock 184!
animals are required.  185!
Resistance of Campylobacter to many common antibiotics, including 186!
ampicillin, streptomycin, tetracycline, erythromycin, gentamycin, and 187!
fluoroquinolones has been reported (Adzitey et al., 2012; Nobile, et al., 2013). 188!
Fluoroquinolone-resistance has especially concerned public health authorities, 189!
because this antibiotic is commonly used as first-line therapy for urinary tract 190!
infection, enteric infection and gonococcal infection (Cheng et al., 2012; 191!
Redgrave et al., 2014). It has been proposed that this resistance is due, in part, 192!
for the use of fluoroquinolones to control mortality associated with Escherichia 193!
coli infection (McDermott et al., 2002), and also to treat colibacilllus and 194!
Mycoplasma infections in poultry (Wagenaar et al., 2006), as a side effect, the 195!
Campylobacter spp present in the gastrointestinal tract of the bird become 196!
resistance. 197!
Usui et al., 2014 reported that treatment of pigs with fluoroquinolones 198!
select to fluoroquinolones-resistance Campylobacter and persist in the GIT after 199!
the treatment for up to 21 days, becoming a significant risk of potential 200!
contamination in humans. 201!
 202!
Virulence mechanisms. 203!
The mechanisms of pathogenesis for Campylobacter are not well 204!
understood. Several proteins have been identified to play an important role in the 205!
adherence mechanism of C. jejuni (Fouts et al., 2005; Parkhill et al., 2000; Young 206!
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et al., 2007). CadF is an outer membrane protein that binds specifically to 207!
fibronection, which is located on epithelial cells (Konkel et al., 1999) and it is 208!
expressed by all C. jejuni and C. coli strains (Dasti et al., 2010). Previous studies 209!
have shown that cadF mutants had significantly reduced capacity to colonize  210!
poultry compared with the wild type strain (Monteville et al., 2003; Young et al., 211!
2007; Ziprin et al., 1999).  CapA (Campylobacter adhesin protein A), JIpA 212!
(Campylobacter jejuni surface lipoprotein A), PEB1 (periplasmic binding protein) 213!
have been identified and suggested to mediate adherence of the bacterium to 214!
epithelial cells (Flanagan et al., 2009; Jin et al., 2003; Pei et al., 1998).  215!
Additionally, other proteins have been described (Cj1270c and Cj1349) to contain 216!
Fn type III domains and act as an Fn and fibrinogen-binding protein (Flanagan et 217!
al., 2009). 218!
The ability of C. jejuni and C. coli to become established in the 219!
gastrointestinal tract of chickens is thought to involve binding and colonization of 220!
the intestinal cell surface (Ganan, et al., 2009; Park, 2002). The mechanisms by 221!
which Campylobacter spp. induce disease in humans is not well understood, but 222!
there are some mechanisms postulated for gastrointestinal disease that involve 223!
bacterial adherence, invasion and colonization of the intestinal mucosa (Park, 224!
2002). The study of Campylobacter pathogenesis is limited by a lack of 225!
understanding of the physiology and virulence factors. Hence, in vivo and in vitro 226!
models with live animals and tissue culture cells have been used as a suitable 227!
alternative to understand the interactions between Campylobacter and the host 228!
epithelium cells. 229!
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Adherence 230!
Adherence is the first, and one of the most important steps in bacterial 231!
pathogenesis (Savage, 1977; Shoaf et al., 2009). Indeed, pathogens that have 232!
lost their ability to adhere generally become avirulent (Casadevall & Pirofski, 233!
2001). At a molecular level, adherence is a receptor-mediated process between 234!
lectin-like bacterial adhesins and their complementary ligands located on the 235!
mucosa surface (Finlay & Falkow, 1989a; Pieters, 2011).  Most bacterial 236!
adhesins are organized as thin thread-like organelles called fimbriae or pili 237!
(Klemm et al., 2010). Importantly, adhesins can be highly specific.  Ultimately, 238!
the specificity of a bacterial pathogen for a particular host or host tissue depends 239!
on the presence of definitive oligosaccharide receptors (Firon et al., 1984; Shoaf 240!
et al., 2006).  Any specific receptor may contain more than one attachment site 241!
for two or more bacterial adhesins (Ofek et al., 2003). Additionally, two different 242!
pathogens can express distinct adhesins that have the same receptor specificity 243!
(Ofek et al., 2003; Wilson, 2002). 244!
Studies on the bacterial adhesion-host receptor interaction have led 245!
researchers to suggest possible strategies to prevent pathogen colonization by 246!
blocking the adhesin-receptor interference.  Thus, agents that inhibit adherence 247!
of foodborne pathogens to the surface of cells have attracted considerable 248!
attention in the past years (Shoaf & Hutkins, 2008).  249!
 250!
 251!
 252!
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Anti-Adherence 253!
The anti-adherence model is based in the observation of the interaction 254!
between bacterial adhesins and host receptors located at the surface of host cell 255!
(Klemm et al., 2010b). One of the anti-adhesive mechanisms that have been 256!
studied is based on the structural similarity that non-digestible oligosaccharides 257!
have to intestinal cell surface receptors (Kunz et al., 2000). Hence, acting as 258!
receptor analogs or decoys that result in blocking the adherence process (Shoaf 259!
et al., 2008) (Figure 1). As a consequence, pathogens bind to the 260!
oligosaccharide decoys and are displaced from the intestinal tract, preventing the 261!
onset of infection (Shoaf & Hutkins, 2009). There is significant evidence that 262!
supports the use of non-digestible oligosaccharides from natural resources (e.g. 263!
human milk oligosaccharides and xyloglucan from berries) and synthetics (e.g. 264!
galactooligosaccharides, N-acetyl-galactosamine, chitooligosaccharides) act as 265!
molecular decoys to inhibit bacterial adherence (Boehm et al., 2005; Newburg et 266!
al., 2005; Quintero et al., 2011; Quintero-Villegas et al., 2013; Shoaf et al., 2006).  267!
Many pathogens utilize monosaccharides or short oligosaccharides as 268!
receptors to bind to the surface of intestinal cells (Sharon, 2006) (Table 1). 269!
 270!
 271!
 272!
 273!
 274!
 275!
! 12!
!
Pathogen Carbohydrates Specificity Target Tissue 
Campylobacter jejuni FucαGalβGlcNAc Intestinal 
Pseudomonas 
aeruginosa L-Fuc Intestinal 
Escherichia coli (Type 1-
fimbriated) Manα3Manα6Man Urinary 
Salmonella spp. (Type 
1-fimbriated) Man Intestinal 
Klebsiella pneumoniae Man 
Respiratory and 
Intestinal 
Neisseria gonorrhoeae Man Genital 
Helicobacter pylori NeuAc(α2-3)Galβ4GlcNAc Stomach 
Streptococcus 
pneumoniae 
[NeuAc(β2-3)]0,1 
Galβ4GlcNAcβ3Galβ4GlcNAc Respiratory 
Neisseria meningitidis [NeuAc(α2-3)0,1 Galβ4GlcNAcβ3Galβ4GlcNAc Respiratory 
Haemophilus influenza [NeuAc(α2-3)0,1 Galβ4GlcNAcβ3Galβ4GlcNAc Respiratory 
Table 1. Carbohydrates attachment sites for bacterial pathogens on animal 276!
tissues. Adapted from (Ofek et al., 2003; Sharon, 2006)     277!
         278!
279!
Figure 1. Anti-adherence model involving receptor analogs molecules for 280!
reducing adherence of pathogens. Adapted from Ofek et al, 2003. 281!
!
!
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Hence, future anti-adherence strategies to prevent pathogen infection 282!
should first focus on identification and characterization of the molecular 283!
interactions between bacterial adhesins and their receptors.  It may then be 284!
possible to identify the specific targets and ultimately synthesize or produce new 285!
molecular decoys that might lead to adherence inhibition. 286!
 287!
 288!
NDO Structure Classification Sources 
β-Glucan 
β-(1!3 and 1!4) D-Glcp 
(Backbone); β-(1!36) D-
Glcp (branches; only on 
some types) 
Soluble, viscous, 
highly 
fermentable. 
Oat bran, barley 
four 
Chitin  β-(1!4)-D-GlcNAc Insoluble, poorly fermentable Shellfish 
Chitosan  β-(1!4)-D-GlcNAc and GlcN 
Soluble and 
viscous/gel-
forming in acid 
solutions 
Alkali-treated 
chitin 
Pectins 
 α-(1!4)-DGalA with 
varying degrees of methyl 
esterification (backbone) 
and side groups 
containing Rha, Gal. 
Soluble, viscous, 
highly 
fermenatable 
Fruits and 
vegetables 
Polydextrose Random polymer of Glc, 
sorbitol, and citric acid 
Soluble, low 
viscosity, partially 
fermentable 
Chemically 
synthesized 
Inulin/Fructo
oligosacchari
des 
Fructose oligo- or polymer 
linked β-(2!1) with Glc at 
the non-reducing end 
Inulin insoluble, 
FOS soluble and 
low viscosity; 
highly fermentable 
Onions, 
Jerusalem 
artichokes, 
Enzymatically 
synthesized 
Galactooligo
saccharides Oliginers of galactose 
Soluble, low 
viscosity, highly 
fermentable 
 Β-
galactosidase 
treatment of 
lactose 
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Lactulose D-Galp-β-(1!4)-D-Fru 
Soluble, low 
viscosity, highly 
fermentable 
Glucose 
isomerase 
treatment of 
lactose 
Arabinoxylan 
Heteropolymer with a 
backborne of β-(1!3 or 
1!4) –D-Xly complex 
branches of Ara, Xyl, GlcA 
and Gal. 
Insoluble or 
soluble and poorly 
to highly 
fermentable. 
Grain-based 
materials, most 
often wheat or 
corn 
Glc, glucose; Gal, galactose; Xyl, xylose; Ara, arabinose; Rha, Rhamnose; GlcA, D- 289!
glucuronic acid; GalA, galacruronic acid; GlcN, D-glucosamine; GlcNAc, N-acetyl-D- 290!
glucosamine. 291!
Table 2. Main Non-digestible Oligosaccharides structure, classification and 292!
sources. (Paeschke & Aimutis, 2011) 293!
 294!
Human milk oligosaccharides (HMO) 295!
Oligosaccharides are the major component in human milk, with a 296!
concentration range of 8-12 g/L (Boehm et al., 2005).  They represent the third 297!
largest compound in milk. HMO are formed from 5 monosaccharides: D-glucose 298!
(Glc), D-galactose (Gal), N-acetylglucosamine (GlcNAc), L-Fucose (Fuc), and 299!
sialic acid (N-acetyl neuraminic acid (Neu5Ac) (Bode, 2006; Engfer et al., 2000). 300!
HMO have a variety of biological activities beyond providing nutrition to the infant 301!
(Barile & Rastall, 2013). There is abundant evidence that HMO can act as a 302!
prebiotic, having a bifidogenic effect in breast-fed infants (Coppa et al., 2006). 303!
Recent studies revealed that the catabolism and fermentation of HMO by 304!
bifodobacteria have unique preferences on these glycans (Barile & Rastall, 2013; 305!
Sela & Mills, 2010; Sela et al., 2011). Moreover, there are several reports 306!
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showing that HMO can also serve as anti-adherence agents against pathogens 307!
by acting as decoys to prevent binding of pathogens to epithelial cells (Barile & 308!
Rastall, 2013; Bode, 2006; Newburg et al., 2004). (Manthey, Autran, Eckmann, & 309!
Bode, 2014) HMOs isolated from pooled human milk was effective to inhibit the 310!
adherence of EPEC (Enteropatogenic Escherichia coli) to cultural epithelial cells 311!
in mice. Interestedly, C. jejuni binds to intestinal epithelial cells using 2’- 312!
fucosyllactosamine receptor (Bode, 2006; Ruiz-Palacios et al., 2003), which is 313!
the most prevalent OS in HMO.  314!
Due to the complexity of the HMO, there has been growing scientific and 315!
industrial interest in natural derived NDO as galactooligosaccharides, 316!
fructooligosaccharides and inulin in the supplementation of infant formulas 317!
(Coppa et al., 2006). 318!
 319!
Galactooligosaccharides (GOS): 320!
GOS have attracted considerable commercial interest, since the presence 321!
of galactose-containing oligosaccharides in human milk has been shown to 322!
enhance the establishment of Bifidobacterium spp in breast-fed infants (Gibson 323!
et al., 2010). Actually, there are several industries that produce GOS from 324!
lactose (purified from cow’s milk whey) using the galactosyltransferase activity of 325!
β-galactosidese to produce several oligomers of different chain lengths 326!
(Macfarlane et al., 2008; Prenosil et al., 1987).  The galactosylation activity of this 327!
enzyme dominates lactose hydrolysis at high lactose concentration (Crittenden & 328!
Playner, 1996; Sako et al., 1999; Smart, 1993). 329!
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The anti-adherence properties of GOS are now well established.  Under in 330!
vitro conditions, GOS inhibited adherence of EPEC (enteropahogenic E. coli) to 331!
HEp-2 and Caco-2 cells by 65% and 70% (Shoaf et al., 2006).  More recently, 332!
Quintero et al., 2011 reported that 16 mg/mL of GOS was also effective against 333!
Cronobacter sakazakii, inhibiting adherence to HEp-2 cells by 56%. Other 334!
studies have shown that adherence of Salmonella enterica serovar typhimurium 335!
to HT-29 cells is inhibited by 5 mg/mL of commercial GOS (Bimuo®) (Searle et 336!
al., 2010). 337!
 338!
Pectic oligosaccharides (POS) 339!
Pectins are commonly found in cell walls and seed mucilage of plants 340!
(Paeschke & Aimutis, 2011). They are commercialized for different industrial 341!
applications due to their potential functional properties. Oligosaccharides derived 342!
from pectins (POS) have gained attention as a candidate prebiotics (Hothkiss et 343!
al., 2003). POS are form by partially methyl esterified homogalacturonan 344!
backbone with periodic interruptions by regions of alternating galacturonic acid 345!
and rhamnose residues (Rastall, 2010).  346!
POS have been assessed for their ability to stimulate growth of beneficial 347!
bacteria, including Lactobacillus (Mandalari et al., 2006) and Bifidobacterium 348!
(Manderson et al., 2005; Olano-Martin et al., 2002). In addition to their putative 349!
prebiotic activity, POS have also been recognized for their ability to inhibit the 350!
adherence of pathogens (Hotchkiss et al., 2003; Holck et al., 2014), as well as for 351!
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their immunomodulatory and anti-carcinogensis properties. (Holck et al., 2014; 352!
Morris et al., 2013).  353!
 354!
Fructooligosaccharides (FOS):  355!
FOS are a mixture of oligosaccharides composed of glucose and 356!
repetitive fructosyl residues in β- (2!1) linkage or β- (2!6) linkage (Boehm et 357!
al., 2005). FOS is naturally present in a variety of food products, including onion, 358!
garlic, salsify, leek, asparagus root, and Jerusalem artichoke tubers (Molis et al., 359!
1996). There are two main industrial processes to obtain FOS. The first one is 360!
produced from sucrose via transfructosylating enzymes and the second one via 361!
partial hydrolysis of inulin by endoglycosidases (Coussement, 1999; Hirayama et 362!
al., 1989; Molis et al., 1996). FOS is one of the best studies NDO in both in vitro 363!
and in vivo models. Like other NDOs, FOS resists hydrolysis, and is able to 364!
reach the colon intact.  In the colon, inulin is fermented by resident symbiotic 365!
anaerobic bacteria, especially bifidobacteria (Walker & Duffy, 1998) (Roberfroid, 366!
1996) 367!
 368!
Chitooligosaccharides (CHOS) 369!
CHOS are produced enzymatically or chemically from chitosan.  370!
Structurally, CHOS consist of a linear heteropolymer of β (1!4) linked N-acetyl- 371!
D-glucosamine (GLcNAc) and its deacylated counterpart D-glucosamine (GlcN) 372!
(Quintero-Villegas et al., 2013). Chitosan is generally produced commercially 373!
from crab and shrimp wastes with different degrees of acetylation and molecular 374!
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masses, thus presenting a variety of properties (Ganan et al., 2009) .  Chitosan 375!
has received increased attention for its natural source and bioactivity, and it is 376!
now used in different applications for foods and pharmaceuticals (Devlieghere et 377!
al., 2004; Ganan et al., 2009). The mechanism behind the bioactivity of CHOS is 378!
poorly understood. However, the sequences of GlcNAc and GLcN units in CHOS 379!
has been reported to be important for binding affinity, and for ensuring selectivity 380!
for pathogens (Aam et al., 2010) 381!
There are several reported studies that have assessed the antimicrobial 382!
properties of CHOS against Campylobacter spp. One study showed that C. jejuni 383!
and C. coli were highly sensitive to chitosan. The minimal inhibitory concentration 384!
(MIC) of chitosan ranged from 0.05% to 0.5% and the most effective 385!
antimicrobial fractions were chitosan with a MM of 120 KDa (Ganan et al., 2009). 386!
Another study reported that the biological properties of CHOS on Campylobacter 387!
depended on the composition of the fraction analyzed (Liu et al., 2008). They 388!
suggested that the high and medium molecular weight of chitosan obtained from 389!
chitosan with a fraction of acetylation (FA) of 0.09 have stronger inhibition effect 390!
compared with the chitosan (FA 0.25) (Mengíbar et al., 2011). 391!
 392!
Mannan oligosaccharides (MOS) 393!
MOS are derived via partial hydrolysis of the polysaccharide, mannan, 394!
which consists of α-1,4 linked mannose monomers (Tester & Al-Ghazzewi, 395!
2013). They are obtained commercially either from plant material or from yeast 396!
cell walls. Mannose-based carbohydrates could be a promising natural agent for 397!
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reducing adherence of enteropathogenic bacteria, since these pathogens rely on 398!
adhesins that bind to mannose receptors (Santin et al., 2001). Yeast 399!
mannanproteins have also been shown to enhance the growth and persistence 400!
of some lactic acid bacteria reach and colonize the gut (Ganan et al., 2012). 401!
Extracts rich in mannanproteins also have shown to inhibit the adherence of 402!
some foodborne pathogens, such as of Campylobacter jejuni (Ganan et al., 403!
2009); E. coli (Baurhoo et al., 2007); and Salmonella (Fernandez et al., 2002; 404!
Posadas et al., 2010). 405!
Arabinoxylan oligosaccharides  (AXOS) 406!
Arabinoxylan (AX) are the second most abundant oligosaccharides in 407!
hemicellulose fraction of softwoods (Faber, 2012). Arabinoxylan oligosaccharides 408!
(AXOS) are derived from wheat bran by extensive hydrolysis of the AX present, 409!
but are not commercially available (Van Craeyveld, 2009). AXOS consists of β- 410!
1,4 linked backbone of xylose with arabinose side chains. 411!
AXOS are similar to other well know inulin and other prebiotic in that they 412!
have shown to have a bifidogenic effect (Grootaert et al., 2007; Paeschke & 413!
Aimutis, 2011; Pastell, et al., 2009; Vardakou et al., 2008). Wheat-derived AX 414!
polysaccharides fractions have been shown to be fermented in vitro by human 415!
fecal microbial communities (Hughes et al., 2008). However, more information 416!
about the structure-activity of both AX and AXOS, and the development of 417!
economically viable process to manufacture these novel oligosaccharides are 418!
required (Paeschke & Aimutis, 2011).   419!
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Cranberry Extract 420!
Cranberry (Vaccinium macrocarpon Ait., family Eri- caceae) fruit juice is 421!
traditionally used to treat and prevent urinary tract infections (Burger et al., 2000; 422!
Howell et al., 2005). Most of the studies have been performed in vitro with 423!
cranberry juice cocktail and concentrated cranberry extract.  These studies have 424!
shown these cranberry products have bactericidal, bacteriostatic and anti- 425!
adhesion properties against different pathogens that colonize the stomach, the 426!
mouth and the urinary tract (Sobota, 1984; Steinberg et al., 2005; Watson & 427!
Preedy, 2010; Zafriri et al., 1989). A-type proanthocyanidins of cranberry juice 428!
cocktail has been shown to inhibit the adherence of P-fimbriated uropathogenic 429!
E. coli to uroepithelial cells.  Therefore, these compounds may be responsible for 430!
the beneficial effect on UTI prevention (Howell et al., 2005; Zafriri, et al., 1989). 431!
The high molecular mass constituents of cranberry juice has been shown 432!
to inhibit adherence of H. pylori BZMC-25 to human erythrocytes by inhibiting the 433!
sialic acid-specific adhesion (Burger et al., 2000). The non-dialyzable material 434!
(NDM) of cranberry extract had been reported as an anti-adhesion and anti- 435!
biofilm agent against S. sorbinus (Steinberg et al., 2005). However, an in-vivo 436!
study showed that dietary supplementation with low (1%) and high (30%) content 437!
of proanthocyanidins from cranberry extract had no significant effect in the 438!
colonization of C. jejuni in young chicks (Woo-Ming, 2012). 439!
Conclusion 440!
 The ability of some non-digestible oligosaccharides to prevent bacterial 441!
adhesion is a promising strategy to interfere with the initial step of bacterial 442!
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pathogenesis. Many well studied NDOs, such as GOS and FOS have been used 443!
as food ingredients for their prebiotic effect, especially to stimulate the growth of 444!
Bifidobacterium spp and to modulate gut microbiota. In addition, other NDOs 445!
have been proposed for their prebiotic properties and also to prevent pathogens 446!
attachment to epithelial host cells. Other oligosaccharides, including natural plant 447!
derived molecules like cranberry extract, have been investigated for their ability 448!
to interfere with the adherence of some pathogens.  449!
Antibiotic growth promoters are used in animal production to enhance 450!
animal performance and reduce pathogens colonization. However, bans and 451!
restrictions on the use of AGPs have led researchers and manufacturers to 452!
identify alternative compounds that have similar function to antibiotics. The anti- 453!
adherence approach has gained considerable interest for agricultural purposes.   454!
Thus, the development of novel natural derived components to prevent 455!
pathogens colonization in animals and human is worthy of exploration.  However, 456!
further investigations are required to understand the structure and functional 457!
properties of anti-adherent agents and the interaction of bacterial adhesins with 458!
the host cell receptors. 459!
Campylobacter spp. are recognized as one of the leading human 460!
foodborne pathogens. Moreover, it is known that this bacterium is well 461!
established in the gastrointestinal tract of poultry, and the consumption of 462!
contaminated meat is the main significant risk factor for human infection. 463!
Therefore, reducing the prevalence of Campylobacter spp. in poultry could 464!
decrease the incidence of campylobacteriosis in humans. NDOs are promising 465!
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agents to be included in poultry diets as a supplement to enhance performance 466!
and reduce adherence of pathogenic bacteria. 467!
The objectives of the research described in this thesis were to: 468!
1. Assess the ability of mannan oligosaccharides (MOS) and cranberry high 469!
molecular weight component (HMW) to inhibit the adherence and invasion of 470!
three strains of C. jejuni and two strains of C. coli to HEp-2 cells. 471!
2. Determine which component (mannan oligosaccharides or β-glucan fraction) is 472!
responsible for the anti-adherence effect. 473!
3. Test the additive effect of a combination of MOS and HMW. 474!
4. Determine the ability of pectic oligosaccharides to inhibit the adherence and 475!
invasion of three strains of C. jejuni and two strains of C. coli to HEp-2 cells. 476!
 477!
 478!
 479!
 480!
 481!
 482!
 483!
 484!
 485!
 486!
 487!
 488!
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Introduction 961!
 962!
Naturally derived non-digestible oligosaccharides (NDO) have attracted 963!
considerable interest among industrial scientists, due to their functional and 964!
biological properties in human food and animal feed.  In particular, these 965!
oligosaccharides have shown to have beneficial effects on animal health by 966!
modulating gut microbiota, suppressing pathogenic bacteria, enhancing 967!
immunity, and facilitating mineral absorption (Paeschke & Aimutis, 2011; Patel & 968!
Goyal, 2011; Van Loo et al., 1999). 969!
In the past decades, sub-therapeutic levels of antibiotics have been widely 970!
used in livestock animals as growth promoters (Dibner & Richards, 2005; Gaggìa 971!
et al., 2010). However, the World Health Organization, the American Medical 972!
Association, and the American Public Health Association have approved these 973!
substances be banned or restricted for animal production applications (Graham & 974!
Boland, 2007). The main motivation for restricting GPAs is due to the 975!
transmission of antibiotic resistant genes among microorganisms that colonize or 976!
infect animals. Ultimately, the spread of pathogenic bacteria that are resistant to 977!
antibiotics would pose significant risks to human health. 978!
Recently, NDOs, and mannan oligosaccharides (MOS), in particular, have 979!
been reported to serve as alternative agents to replace growth promoting 980!
antibiotics in animal production (Patel & Goyal, 2011; Yang et al., 2009,  Baurhoo 981!
et al., 2007; Ferket et al., 2002; Kim et al., 2011; Miguel et al., 2004; Soren et al., 982!
2013). MOS are derived from the yeast cell walls (Feuillat, 2003), and are 983!
inexpensive by-products from industrial processes (i.e. brewers, bakeries). 984!
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Several studies have shown beneficial effects of MOS supplementation in animal 985!
feed, such as reduce the colonization of some pathogens like E. coli and 986!
Salmonella spp. (Fernandez et al., 2002; Line et al., 1998; Santin et al., 2001), 987!
immune modulation (Sang et al., 2009; Staykov et al., 2007), and improve growth 988!
performance and welfare in livestock (Sang & Fotedar, 2010; Torrecillas et al., 989!
2011; Zhao et al., 2012). 990!
The present review paper describes the main applications of mannan 991!
oligosaccharides in animal feed and their role as alternative components to 992!
replace growth-promoting antibiotics. 993!
 994!
Mannan oligosaccharides 995!
Mannan oligosaccharides (MOS) are non-digestible oligosaccharides 996!
derived via partial hydrolysis of the polysaccharide, mannan (Tester & Al- 997!
Ghazzewi, 2013a).  The latter consists of α-1,4 linked mannose monomers.  998!
Partial hydrolysis yields MOS with degree of polymerization (DP) ranging from 6 999!
to 8 (Bland et al., 2004).  Currently, most commercial sources of MOS are 1000!
derived from the cell walls of bakers’ or brewers’ yeast strains of Saccharomyces 1001!
cerevisiae.  They are used primarily as supplements for animal feed (Halas & 1002!
Nochta, 2012). The actual composition of yeast-derived MOS depends on 1003!
several factors, including species, growth phase at harvest, and growth or 1004!
fermentation conditions. 1005!
Other sources of MOS have also been considered.  Plant-derived MOS 1006!
have been studied from hemicellulose plant cell walls, such as konjac (Holck et 1007!
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al., 2014).  Spent coffee grounds, coffee beans and waste coffee mannans have 1008!
also been studied (Moreno & Sanz, 2014), but no commercial sources for these 1009!
products currently exist. 1010!
 1011!
MOS from yeast cell wall 1012!
The yeast cell wall is a major constituent of the total yeast biomass, 1013!
accounting for 25 - 30% of dry weight of the cell (Klis et al., 2010; Latgé, 2007) . 1014!
Yeast cell walls of S. cerevisiae are composed of mannoprotein (35%), β-1,3 1015!
glucan (25%), β-1,3 glucan bound to chitin (35%),  β-1,6 glucan (5%)  and small 1016!
amount of chitin (1-2%) (Feuillat, 2003; Orlean, 2012).  1017!
 The cell wall proteins exist as glycoproteins that are highly modified with 1018!
O-and N-linked oligosaccharides. These oligosaccharides are comprised mainly 1019!
of mannose residues, collectively known as mannan (Gupta et al., 2012). The 1020!
mannan backbone is homopolymeric, containing mannose residues only or 1021!
heteropolymeric, with side chains containing other sugars.  The latter include 1022!
mannose, glucose, rhamnose, and galactose, forming glucogalactomannan, 1023!
rhamnogalactomannan, and galactomanan oligosaccharides (Bowman & Free, 1024!
2006; Gupta et al., 2012; Leal et al., 2010). 1025!
Many of the proteins found in yeast cell walls are water-or detergent-soluble, 1026!
and only a few are covalently linked to the polysaccharides. These glycoproteins 1027!
are classified in two groups: proteins covalently linked to β-1,3 glucan through 1028!
glutamine reside; and proteins covalently linked by a glycosylphophatidyl inositol 1029!
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anchor to the β-1,6 glucan of a β-1,3/ β-1,6 glucan core (Gupta et al., 2012; Klis 1030!
et al., 2006; Latgé, 2007). 1031!
 1032!
Biological properties of MOS 1033!
Although non-digestible oligosaccharides, MOS have no known direct 1034!
nutritive value in animal feed, however, they have been suggested to enhance 1035!
gut health (Halas & Nochta, 2012).  Several properties of MOS that make them 1036!
useful as nutritional supplements for animal feed products have been described 1037!
(Table 1) (Ferket et al. 2002 and Soren et al. 2013).  In general, MOS should be 1038!
non-digestible, not absorbed in the stomach and small intestine, and they should 1039!
reach the colon intact.  In the colon, MOS and mannose-based glycans could 1040!
have prebiotic activity and be fermented by desirable members of the gut 1041!
microbiota.   1042!
The yeast-derived MOS and β-glucan components share similar 1043!
properties, but are different in several important respects.  MOS are 1044!
polysaccharides-protein complexes, and β-glucans are polymers of glucose. β- 1045!
glucans have been considered as immunoestimulators of macrophages and 1046!
other immune effector cells (Chong, 2009). Szymanska-Czerwinska et al., 2009 1047!
have reported that the combination of MOS and β- glucans increase cytokine 1048!
levels and the percentage of lymphocyte subpopulation in calves. More recent 1049!
study made by Zhang et al., 2012 shown that broiler chickens fed with β-glucans 1050!
from yeast cell wall enhance cell mediated immune response by modulating the 1051!
production of cytokines. 1052!
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Several studies have suggested another important property of MOS.  1053!
Specifically, mannan oligosaccharides can inhibit the binding of pathogenic 1054!
bacteria to the mucosa of the gut and therefore reduce colonization and the 1055!
onset of infections (Klemm & Schembri, 2000; Tester & Al-Ghazzewi, 2013b). In 1056!
the GIT, MOS act as high affinity ligands, providing competitive binding sites for 1057!
specific enteric bacteria (Ofek & Beachey, 1978). This binding is usually 1058!
mediated by bacterial fimbriae that contain terminal adhesin residues.  Fimbriae 1059!
thus serve as adhesive organelles that enable bacteria to target specific host 1060!
tissues, to which they bind to and colonize (Corrigan et al., 2012).  Mannose 1061!
residues are bound preferentially by type I fimbria, present in several enteric 1062!
pathogens.  1063!
Extracts rich in mannoproteins have been shown to be effective, in vivo, 1064!
against Campylobacter jejuni (Ganan et al., 2009; McSweegan & Walker, 1986) , 1065!
Escherichia coli (Baurhoo et al., 2007) and Salmonella (Fernandez et al., 2002; 1066!
Oyofo et al., 1989). Most of these in vivo studies have been conducted with 1067!
broiler chicks, pigs, fish, cattle, and companion animals. Dietary 1068!
supplementations with MOS from yeast extracts have been used in livestock 1069!
animals at relatively low concentrations (between 0.5 - 5.0 kg/ton), resulting in 1070!
enhanced overall performance and reduced inhibition and colonization of enteric 1071!
pathogens (Baurhoo et al., 2007; Castillo et al., 2008; Torrecillas et al., 2011; 1072!
Waldroup et al., 2003; Zhao et al., 2012). 1073!
 1074!
 1075!
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MOS production 1076!
As noted above, most of the commercial MOS products are derived from 1077!
various strains of yeast. The most common yeasts used for MOS product are 1078!
from the genus of Saccharomyces and Candida. In general, yeast cells are 1079!
grown using common techniques used in the bakers yeast and brewers yeast 1080!
industries (Halas & Nochta, 2012).  Nutrient-rich media are used to achieve high 1081!
cell densities, and often include diluted molasses and sulfite waste liquor. Once 1082!
cell growth has reached a sufficiently high cell density, the yeast cell wall fraction 1083!
(containing MOS) is extracted. This is usually done by mechanical or enzymatic 1084!
methods and rely on autolysis, hydrolysis (i.e., via β–mannanases, pectinases, α- 1085!
galactosidases and cellulases) or physical means (Katz & Brown, 2007) 1086!
Autolysis of yeast cell wall is one of the most common methods to extract 1087!
the MOS fraction.  For example, Agrimos®, manufactured by Lallemand Animal 1088!
Nutrition, is produced by autolysis of yeast cells at high temperatures and at 1089!
controlled pH.  The yeast extract and cell wall is separated by centrifugation, and 1090!
the cell wall fraction is spray dried and packaged. 1091!
 1092!
Antibiotics in animal production  1093!
Antibiotics have been used to promote growth in livestock animals for 1094!
many decades (Ferket et al., 2002). In vivo studies have reported that inclusion 1095!
of regular low doses of antibiotics in animal diets provides several beneficial 1096!
performance effects in animals, including increases in weight gain, improved feed 1097!
efficiencies, reduced mortality, and inhibition of pathogen colonization in 1098!
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intensive production systems (Gaskins el al., 2002; Phillips et al., 2004). 1099!
Ultimately, these benefits are suggested to reduce overall animal production 1100!
costs and to provide economic benefits that are distributed along the food chain 1101!
(Ferket, 2003). However, the widespread use of antibiotics in animal production 1102!
has also been suggested to contribute to the emergence and spread of antibiotic 1103!
resistance bacteria (Phillips et al., 2004). 1104!
Controlling the transmission of pathogenic bacteria at the farm level is now 1105!
a major of concern in animal production. In particular, the poultry industry has 1106!
identified contamination of raw poultry products to be a consequence of high 1107!
populations of pathogenic bacteria in the gastrointestinal tract of poultry animals 1108!
(Ferket et al., 2005). 1109!
 1110!
Mode of action of growth promoters  1111!
Although widely used in animal agriculture (Looft et al., 2012), the 1112!
mechanisms by which antibiotics promote growth are not fully understood 1113!
(Dibner & Richards, 2005; Graham & Boland, 2007).  Many hypothesis have 1114!
been suggested to explain the mechanisms of action for the growth-promoting 1115!
effect of antibiotics in production animals (Giguère et al., 2013) 1116!
 Gaskins et al, 2002 proposed four mechanisms of action of GPAs: (1) 1117!
inhibition of sub-clinical infections; (2) reduction of growth-depressing microbial 1118!
metabolites; (3) reduction of microbial use of nutrients; and (4) enhanced uptake 1119!
and use of nutrients.  More recently, Giguère et al., (2013) suggested additional 1120!
hypotheses to account for the growth-promoting effect of antibiotics in livestock 1121!
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animals (Table 1), such as: stimulation of intestinal synthesis of vitamins by 1122!
bacteria; reduction in total number of bacterial in the GIT by reducing competition 1123!
between microorganism and host animals for nutrients; reducing pathogenic 1124!
bacterial; inhibition of bacterial urease; improve energy efficiency of the gut; 1125!
reduced immune stimulation; modification of intestinal enzyme activity; inhibition 1126!
of bacterial cholytaurin hydrolases activity; improve nutrient absorption from 1127!
morphological changes to small intestinal epithelium.  In contrast, Bedford, 2000 1128!
reported that GPAs have no beneficial effect in germ-free chicks, indicating that 1129!
the direct effect is due to alteration in the gut microbiota composition rather than 1130!
interact with the physiology of the animal (Conejos et al., 2012). 1131!
 1132!
Effects of antibiotics in animals  1133!
After antibiotic administration, animals are more susceptible to pathogens 1134!
colonization because of the loss of the resident microbiota (Ferket, 2004). The 1135!
stability of the gut microbiota is important for maintenance of a healthy barrier 1136!
against pathogen infection in animals (Gaggìa et al., 2010). Administration of 1137!
competitive exclusion cultures as probiotics (Fedorka-Cray et al., 1999; Sohail et 1138!
al., 2010) or feeding prebiotic oligosaccharides have been used in livestock to 1139!
enhance the stability of microbiota (Ferket, 2004; Fernandez et al., 2002).  1140!
Accordingly, older animals are, in general, more resistant to colonization by 1141!
enteric pathogens than young animals because they have more stable diverse 1142!
gut microbiota that compete excluding pathogen colonization (Ferket, 2004).  1143!
 1144!
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MOS as new growth promoter agent 1145!
Since the use of antibiotics has been banned in Europe and some have 1146!
been restricted in United States, there are serious concerns about the possibility 1147!
that antibiotic-resistant genes can be transferred to human pathogens 1148!
(Chowdhury el al., 2009). Hence, the animal production industry has been 1149!
seeking to identify or develop alternative products to reduce reliance on 1150!
antibiotics while maintaining production efficiency (Ferket et al., 2005). 1151!
MOS may be an effective alternative to replace antibiotic growth 1152!
promoters (AGPs), because they have been shown to have similar effect on 1153!
animal performance (Baurhoo et al., 2007; Castillo et al., 2008; Fritts & 1154!
Waldroup, 2003). MOS were first introduced as a feed additive for poultry in 1993 1155!
(Bio-MOS®, Alttech Inc.). This carbohydrate has been recognized to have 1156!
potential properties to inhibit the adherence pathogen to the surface of epithelial 1157!
cells.  1158!
 1159!
Alternatives to antibiotics in poultry production 1160!
Although the use of antibiotics as growth promoters in the poultry industry 1161!
has been widely accepted for many years, there is now considerable concern 1162!
about their possible effects on public health (Dibner & Richards, 2005). 1163!
Proponents of this practice have suggested that GPAs are an essential tool to 1164!
maintain animal productivity by increasing average weight of broilers, reducing 1165!
the amount of feed required to reach market weight, and ultimately decreasing 1166!
the cost of chicken products for consumers (Graham & Boland, 2007; Smith, 1167!
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2002). However, alternative inexpensive and natural agents are now being used 1168!
for pathogen control and to enhance the overall performance of the animal and 1169!
replace the use of GPAs. These include probiotics and prebiotics, herbal 1170!
products, vaccines, and sanitation practices to prevent vertical transmission of 1171!
pathogens and promote gut health (Stanley & Jones, 2003; Yano et al., 2013).  1172!
 1173!
MOS in poultry production 1174!
Mannan oligosaccharides products, especially those derived from the cell 1175!
wall of S. cerevisiae, are extensively used as natural feed additives in poultry due 1176!
to the beneficial effect in the performance and gastrointestinal health (Xiao et al., 1177!
2012). However, studies have shown contradictory results in chickens and 1178!
turkeys. In some studies, supplementation of MOS in the diets had significant 1179!
effects on the performance (i.e., increase in body weight, feed conversion, feed 1180!
intake) of the animal (Baurhoo, et al., 2007; Fernandez et al., 2002; Waldroup et 1181!
al., 2003).  Similarly, decreases in pathogenic bacteria in the gut, stimulation of 1182!
the immune response, and elevating the strength of the intestinal mucosa have 1183!
also been reported (Corrigan et al., 2012; Fernandez et al., 2002; Fritts & 1184!
Waldroup, 2003). In contrast, other studies that reported that there was no 1185!
significant effect when MOS was included in the diets of poultry compared with a 1186!
normal diet or with diet with antibiotic supplementation (Table 1).   1187!
 1188!
 1189!
 1190!
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MOS in swine production  1191!
In swine nutrition, supplementation of feed with prebiotics and probiotics 1192!
have been reported to have beneficial effects on growth performance, 1193!
gastrointestinal functional, and health of pigs (Zhao et al., 2012). Previous 1194!
studies have demonstrated that mannan oligosaccharides improved the daily rate 1195!
of weight gain and/or feed efficiency during early stages of nursery pigs (Davis et 1196!
al., 2002; Miguel, Rodriguez et al., 2004; Zhao et al., 2012) and in sow diets 1197!
during late gestation and lactation (Halas & Nochta, 2012). However, there are 1198!
other studies that reported less consistent results, specifically, that MOS had no 1199!
effect in the performance of young pigs (Castillo et al., 2008; Wenner et al., 1200!
2013). Although, there are some conflicting results with the effect of MOS as a 1201!
growth promoter in pigs, other studies have shown that the supplementation with 1202!
MOS in the diet reduce the total coliforms counts in the gut and appears to have 1203!
immune modulation effect in the post weaning-period in pigs (Davis et al., 2004; 1204!
Kim et al., 2011) (Table 2). 1205!
Weaning is a critical period in piglets that is associated with stress, 1206!
diarrhea, and depressed growth rates (Liu et al., 2008). Antibiotics have long 1207!
been used to control and prevent these post weaning symptoms. MOS as a feed 1208!
additive are suggested to be an alternative of the GPAs in swine, based on the 1209!
relevant literature that have shown these products maintain gut health, interfering 1210!
with pathogen colonization and enhancing the defense mechanisms in post 1211!
weaning pigs and in other livestock animals. 1212!
 1213!
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MOS in fish production  1214!
Aquaculture production have been recognize as a growing industrial 1215!
sector that have a huge socio-economic impact in developing and emerging 1216!
countries (Yousefian & Amiri, 2009).  Indeed, one of the most important priorities 1217!
in the aquaculture industry is to produce fish and seafood under sustainable and 1218!
safe conditions. As for poultry and swine, feed supplements are needed to 1219!
improve animal health, reduce mortality, improve growth performance, and 1220!
reduce or eliminate antibiotics in the diets (Torrecillas et al., 2007). The use of 1221!
non-digestible oligosaccharides have shown promise as preventive and 1222!
environmentally friendly alternatives to antibiotics in aquaculture, and to improve 1223!
overall health especially for fishes and crustacean (Bachere, 2003; Soltanian et 1224!
al., 2007) that may lead to expand and maintain this industry. 1225!
The mechanism of action of MOS in fish production appears to be similar 1226!
to other animal applications.  These products may prevent pathogen colonization, 1227!
enhance overall health and welfare, and promote gut maturation and growth 1228!
(Genc et al., 2007; Sado et al., 2008; Torrecillas et al., 2011). Incorporation of 1229!
MOS in the diet has been reported to promoted resistance to bacterial infection in 1230!
Cobia (Rachycentron canadum)(Salze et al., 2008), rainbow trout (Salmo 1231!
gairdneri irideus) (Staykov et al., 2007), sea bass (Dicentrarchus labrax) 1232!
(Torrecillas et al., 2011), channel catfish (Ictalurus punctatus) (Peterson et al., 1233!
2010), marron (Cherax tenuimanus) (Sang et al., 2009). However, other studies 1234!
showed no effect of MOS on growth performance of aquatic species ( a 1235!
Dimitroglou et al., 2009; Pryor, 2003). For example, investigations with Gilthead 1236!
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sea bream (Sparus aurata) (A. Dimitroglou et al., 2010), Atlantic salmon 1237!
(Grisdale-Helland, et al., 2008) revealed no significant effect when 1238!
supplementing diets with MOS. 1239!
 1240!
Conclusion 1241!
The worldwide trend toward eliminating the uses of antibiotic growth 1242!
promoters for animal production has led researchers to seek new strategies to 1243!
enhance growth, increase feed efficiency, reduce pathogen colonization, and 1244!
improve overall performance in livestock animals. Mannan oligosaccharides are 1245!
naturally derived molecules that may have the properties necessary to provide 1246!
benefits similar to antibiotics.  However, further research must be conducted to 1247!
identify the function and mechanism of action of these substances.  Ultimately, 1248!
the use of MOS and other similar material to inhibit specific pathogens in 1249!
livestock animals may have important implications for improving food safety. 1250!
 1251!
 1252!
 1253!
 1254!
 1255!
 1256!
 1257!
 1258!
 1259!
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Table 1.  In vivo uses of mannan oligosaccharides in poultry 1533!
 1534!
Diet Performance Gut Health References 
0.2% MOS 
BioMOS 
Significant 
improvement on feed 
conversion. No effect 
on body weight, 
mortality and breast 
meat yield. 
Increased the 
population of 
bifidobacteria and 
lactobacilli in the 
ceca, after 42 days 
of treatment 
(Baurhoo et 
al., 2007) 
0.1% MOS 
BioMOS 
Higher body weight 
gain, better feed 
conversion in broiler 
chickens and higher 
villus height at 7 days 
of age. 
No reported (Waldroup et al., 2003) 
0.2% MOS No reported 
S. enteritidis 
colonization 
decreased over 
time in chick fed 
with MOS diet. 
(Santin et al., 
2002) 
2.5 % MOS 
Body weight gain, feed 
intake and feed 
conversion ratio of 
broilers by adding 
MOS are not 
significant different (6 
weeks) 
Increased 
Bifidobacterium 
spp., while 
decreasing member 
of 
Enterobacteriaceae 
and Enterococcus 
spp., 
(Fernandez et 
al., 2002) 
0.15% MOS 
Body weight and feed 
conversion ratio are 
no significantly 
affected by the MOS 
diet. 
No reported  (Yalcinkaya et al., 2008) 
0.10 % BioMOS 
Significant 
improvement in feed 
conversion after the 
20 week of inclusion of 
MOS. Body weight 
gain and mortality are 
no significantly 
affected by the 
treatment. 
No reported 
(Fritts and 
Waldroup, 
2003) 
0.22% MOS 
BioMOS No reported 
Identified 672 
genes expressed in 
the jejunum by 
(Xiao et al., 
2012) 
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 1535!
 1536!
 1537!
 1538!
 1539!
 1540!
 1541!
 1542!
 1543!
 1544!
 1545!
MOS 
supplementation 
that are involved in 
the diverse 
biological functions 
including energy 
production, cell 
death, and protein 
translation. 
0.1% Yeast S. 
boulardii 
No significant 
differences in body 
weight, and feed 
conversion ratios. 
Significant 
reduction in the 
colonization of 
challenged 
Salmonella 
typhimurium in 
chickens fed with 
MOS diet. 
Campylobacter 
jejuni colonization 
was not significantly 
affected with the 
diet. 
(Line et al., 
1998) 
0.1% MOS 
(BioMOS) No reported 
MOS 
supplementation 
displayed 
significantly altered 
bacterial community 
structure in young 
turkeys. 
(Corrigan et 
al., 2012) 
0.3 and 0.5% 
MOS (BioMOS) 
The MOS supplement 
let to minor 
improvement in body 
weight but no 
improvement in feed 
conversion ratio. 
No reported (lji et al., 2001) 
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Table 2. In vivo uses of mannan oligosaccharides in pigs 1546!
  1547!
Diet Performance Gut Health References 
0.2 % MOS 
BioMOS 
Improve efficiency of 
weight gain during 
starter period of 
piglets. 
Decreased 
enterobacteria 
counts in jejunum. 
(Castillo et al, 
2007) 
0.1% MOS 
Significant 
improvement in 
average daily gain 
and average daily 
gain intake in pigs fed 
with MOS during 28 
days. 
No reported (Zhao et al, 2013) 
0.2% MOS 
BioMOs 
No statistical 
difference in growth 
rate, average daily 
feed intake and feed 
conversion in weaning 
pigs fed with MOS 
diet. 
No reported (Wenner et al, 2013) 
0.2% MOS 
Improve in daily feed 
intake during the 
starter period (2 
weeks). 
Feed conversion was 
improved. 
Pigs fed with MOS 
diet decreased 
enterobacteria 
counts in the 
jejunum. 
(Castillo et 
al., 2007) 
0.2% MOS 
Increased average 
daily gain and 
average daily feed 
intake of nursery pigs 
between 12 to 14 
days of MOS diet. 
No reported  (Lemieux et al., 2003) 
3 % brewers 
dried yeast 
None effect in the 
growth performance 
of nursery pigs. 
Total coliforms, 
Escherichia coli, and 
Clostridium 
perfringens in feces 
were not affected by 
diet. Bifidobacteria 
spp. counts were 
lower in pigs fed the 
yeast diet and 
lactobacilli counts 
were higher in pigs 
fed yeast. 
 (White et al., 
2002) 
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 1548!
 1549!
 1550!
 1551!
 1552!
 1553!
 1554!
 1555!
 1556!
 1557!
 1558!
 1559!
 1560!
 1561!
 1562!
0.2% MOS 
Average daily gain, 
average daily feed 
intake and gain: feed 
ratio increased with 
MOS diet from day 0 
to 10 in weanling pigs. 
No reported (Davis et al., 
2002) 
0.3 % MOS 
Increased the average 
daily gain and 
average daily feed 
intake in the pigs fed 
with MOS diet 
No reported 
 
 
(Rozeboom 
et al, 2005) 
0.3% MOS No reported 
Increases of 
apparent coefficient 
of digestibility, and 
in villi height of the 
animals fed with 
MOS. 
(Conejos et 
al, 2012) 
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Table 3. In vivo uses of mannan oligosaccharides in fish and crustacean. 1563!
 1564!
Diet Performance Gut Health References 
0.2% MOS No reported 
Viable intestinal 
bacterial population 
was significant 
reduced (approx. 2 
Logs) like  
Aeromonas/Vibrio 
spp. in juvenile trout 
fed with MOS. 
(Staykov et 
al., 2007) 
0.2% and 0.4% 
MOS BioMOS 
Fish fed with 0.2% 
and 0.4% MOS 
shown significant 
increase body weight 
and growth rate. 
European sea bass 
intestinal villi length 
was no affected by 
MOS diet. 
0.4% MOS 
significantly improved 
head kidney 
macrophages 
phagocytic activity. 
Significant reduction 
in the challenge of V. 
alginolyticus in 
presence of 0.4%. 
(Torrecillas et 
al., 2007) 
0.2% and 0.4% 
MOS 
No significant effect 
in the body weight, 
feed conversion, and 
specific growth rate 
and protein 
efficiency ratio in sea 
bream fed with MOS 
diet for 9 weeks. 
MOS diet increased 
microvilli density in 
both the anterior and 
posterior. intestinal 
regions. No 
significant effect in 
the gross of villi 
structure. 
MOS diet alters the 
intestinal microbiota 
and morphology of 
gilthead sea bream. 
(Dimitroglou 
et al., 2010) 
 
Fish fed diets with 
0.4% MOS had best 
weight gain but it is 
no significant 
different from the 
No reported (Sado et al., 
2008)  
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 1565!
 1566!
 1567!
control. Feed 
conversion decrease 
with the increase 
levels of MOS. 
0.3% MOS 
Enhanced growth 
performance and 
feed conversion ratio 
was observed in 
shrimp fed with MOS 
for 48 days. 
No reported (Genc et al., 
2011)  
0.4 % and 0.6 % 
MOS 
Feed consumption 
was improved in fish 
feed with MOS.  
Reduction in feed 
intake was found in 
fish with the inclusion 
of MOS. 
Enhancement in the 
number of cells 
secreting acid mucins 
in posterior gut of fish 
fed MOS. 
(Torrecillas et 
al., 2011)  
0.3% MOS 
No significant effect 
in the growth 
performance in fish 
fed with MOS. 
No significant effect 
in the gastrointestinal 
morphology or spiral 
valve villi structure 
was found in fish fed 
with MOS 
supplementation. 
 
(Pryor, 2003) 
0.4% MOS No reported 
Gut mucosal folds 
height, width and 
folds surface area 
were increased in fish 
fed with MOS diet 
during 8 weeks 
Enhancement in the 
number of cells 
secreting acid mucins 
and in gut mucus 
lysozyme activity. 
(Torrecillas et 
al., 2011)  
0.4% MOS 
Significant higher 
growth rate and 
average weekly gain 
in lobster fed with 
MOS for 56 days 
Lower mortality of 
lobster fed with MOS 
when Vibrio spp was 
challenge for 7 days.  
(Sang and 
Fotedar, 
2010) 
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Chapter 3 1583!
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Adherence inhibition of Campylobacter jejuni and Campylobacter coli to HEp- 1585!
2 cells by mannan oligosaccharides and cranberry high molecular weight 1586!
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Abstract 1608!
Campylobacter infections are a leading cause of human bacterial gastroenteritis 
in the United States and a major cause of diarrheal disease throughout the world. 
Poultry has been identified as a major reservoir for this pathogen, and 
contaminated chicken meat is considered a significant risk for human infection. 
Colonization and subsequent infection and invasion of Campylobacter require 
that the organism adheres to the surface of host cells as the first and one of the 
most important steps in bacterial pathogenesis. Agents that inhibit adherence 
could therefore be used prophylactically to reduce Campylobacter carriage and 
infection. Yeast mannan oligosaccharides (MOS) have been used as a feed 
supplement in livestock animals to replace growth-promoting antibiotics. 
However, some non-digestible oligosaccharides as MOS may also have the 
ability to prevent gastrointestinal infections by inhibiting pathogen adherence. 
Cranberry juice has been used to treat and prevent urinary tract infections, due in 
part to a high molecular weight (HMW) fraction that has anti-adherence activity 
against pathogens. The goal of this study was to assess the ability of MOS, 
purified MOS, cranberry HMW and the combination of MOS and HMW to serve 
as anti-adherence agents against C. jejuni ATCC 29428, C. jejuni ATCC 33291, 
C. jejuni ATCC 700819, C. coli ATCC 43485 and C. coli ATCC BAA-1061. 
Adherence experiments were performed using a human epithelial tissue cell line 
(HEp-2) in the absence or presence of MOS, pMOS, HMW and MOS/HMW. 
Significant reductions in adherence of C. jejuni ATCC 29438, C. jejuni ATCC 
700819, C. jejuni ATCC 3329 and C. coli ATCC 43485 were observed in the 
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presence of MOS/pMOS (up to 40 mg/mL) and with HMW (up to 3 mg/mL). 1609!
There was no significant effect in the adherence of C. coli ATCC BAA-1061. 1610!
There was no additive effect in adherence of all the strains with the blend of 1611!
MOS/HMW. The results obtained in this work suggest that MOS, pMOS and 1612!
HMW may have an anti-adhesive effect on specific strains of C. jejuni and C. coli 1613!
and directly inhibit the adherence to HEp-2 cells. These results suggest that both 1614!
components MOS and HMW could be used to reduce Campylobacter 1615!
colonization in livestock animals and prevent the onset of human infections. 1616!
 1617!
Introduction 1618!
Mannan oligosaccharides (MOS) are non-digestible oligosaccharides 1619!
derived via partial hydrolysis of the polysaccharide, mannan (Tester & Al- 1620!
Ghazzewi, 2013).  The latter consist of α-1,4 linked mannose monomers and are 1621!
obtained commercially either from plant material or from yeast cell walls.  In 1622!
particular, brewers’ and bakers’ yeast strains of Saccaromyces cerevisiae are 1623!
widely used to produce MOS products for animal nutrition applications (Halas & 1624!
Nochta, 2012). Yeast cell walls of S. cerevisiae are composed of mannoprotein 1625!
(35 %), β-1,3 glucan (25%), β-1,3 glucan bound to chitin (35%),  β-1,6 glucan 1626!
(5%)  and small amount of chitin (1-2%) (Feuillat, 2003; Orlean, 2012). 1627!
 Mannose-based carbohydrates could be a promising natural agent for 1628!
reducing adherence of enteropathogenic bacteria, since because bacterial 1629!
adherence in the gut is often mediated by binding of bacterial lectins to receptors 1630!
containing D-mannose (Ganan et al., 2012; Shoaf et al., 2006). MOS as non- 1631!
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digestible oligosaccharide have no direct nutritive value in animal feed, however 1632!
they have been shown to maintain or promote gut health (Halas & Nochta, 2012). 1633!
Extracts rich in mannanproteins have been shown to have a bioprotective effect 1634!
against some pathogens such as Campylobacter jejuni (Ganan et al., 2009; 1635!
Mcsweegan, 1986; Russell & Blake, 1994), Escherichia coli (Baurhoo et al, 2007) 1636!
and Salmonella (Fernandez et al., 2002; Oyofo et al., 1989). Most studies have 1637!
been conducted in-vivo with broiler chicks and pigs, and to a less extend in cattle 1638!
and swine. Dietary supplementations with mannan oligosaccharides from crude 1639!
yeast extract have been used in livestock animals, resulting in enhance overall 1640!
performance and inhibiting colonization of enteric pathogens. 1641!
Another natural source of anti-adherence substances is derived from 1642!
cranberry juice. Cranberry fruit juice has traditionally been used to treat and 1643!
prevent urinary tract infections (UTI) (Vinson et al., 2008; Zafriri et al., 1989). In 1644!
particular, two main components in cranberry juice have been shown to reduce 1645!
adherence of E. coli to uroepithelial cells. Fructose inhibits adherence of E. coli 1646!
phenotypes possessing type 1 (mannose-sensitive) fimbriae (Foo et al., 2000; 1647!
Zafriri et al., 1989), and type-A proanthocyanidins (PACs) inhibits adherence of 1648!
P-fimbriated E. coli  in vitro (Howell et al., 2005). Thus, these compounds may be 1649!
responsible for the beneficial effect of cranberry juice on UTI prevention. 1650!
Cranberry PACs have unusual A-type linkages compared to the more 1651!
common B-type linkages found in PACs from other tannin-rich foods (Foo et al., 1652!
2000; Howell et al., 2005). There are no existing data about the anti-adherent 1653!
effect of B-linkage proanthocyanidins against pathogenic microorganism. 1654!
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Cranberry PACs consists of epicatechin unids (epicatechin-(4β-8, 2β-O-7)- 1655!
epicatechin-(4β-8)) (Duarte et al., 2006) with degree of polymerization (DP) of 4 1656!
and 5 and at least one A-type linkage (Seeram et al., 2004). The mode of action 1657!
of the cranberry type-A PACs is still unknown, however, it has been suggested 1658!
they act by hydrophobic interactions, which modify bacterial surface 1659!
macromolecules like fimbria and lipopolysaccharides (Steinberg et al., 2005), 1660!
reducing adherence to epithelial cells.   1661!
Steinberg et al., 2005 observed anti-adherence and anti-biofilm formation 1662!
activity against Streptococcus sobrinus by cranberry high molecular weight 1663!
component (15000 MW cutoff) also known as nondialyzable material (NDM). 1664!
Another study reported that cranberry juice inhibited the adherence of 1665!
Helicobacter pylori to human gastric mucus and to human erythrocytes (Burger et 1666!
al., 2000). 1667!
Campylobacter jejuni and Campylobacter coli are among the leading 1668!
human foodborne pathogens (Leblanc-Maridor et al., 2011) and have been 1669!
implicated as the most common cause of gastroenteritis in developed countries. 1670!
The consumption of chicken contaminated with Campylobacter is considered a 1671!
major risk factor for human infection (Friedman et al., 2000). Although 1672!
Campylobacter infections have low mortality, about 76 people die each year from 1673!
Campylobacter infections (CDC, 2013). In addition to causing gastroenteritis, 1674!
Guillain-Barré syndrome (GBS) is the most significant implication of 1675!
Campylobacter jejuni infections (Buzby et al., 1997; Mawla et al., 2014). It is a 1676!
rare autoimmune disease that affects the peripheral nervous system causing 1677!
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muscle weakness and paralyses. Around 40% of the cases of GBS in United 1678!
States are due to previous campylobacteriosis (Buzby et al., 1997; CDC, 2013). 1679!
It is estimated that approximately one every 1,000 cases of reported 1680!
Campylobacter illness leads to GBS (CDC, 2013). 1681!
The mechanisms of pathogenesis for Campylobacter are not well 1682!
understood.  However, adherence to host epithelial cell is the first and perhaps 1683!
the most important step for bacterial colonization and infection. Thus, there is a 1684!
considerable interest in identifying preventive strategies to mitigate 1685!
Campylobacter infection in humans.  One approach would be to reduce 1686!
colonization of this organism in poultry, and the anti-adherence approach using 1687!
non-digestible oligosaccharides and naturally derived molecules could be a 1688!
potential solution.  MOS, in particular, have been suggested to be effective anti- 1689!
adherence agents. 1690!
Although anti-adherence strategies have been proposed for several 1691!
human and animal applications, this approach has one important limitation.  1692!
Specifically, it is known that pathogenic bacteria often encode and express genes 1693!
for more than one type of adhesin, a process known a phase variation 1694!
(Henderson et al., 1999). Hence, it may be more effective to target more than 1695!
one adhesion, by using a mixture of different anti-adherence agents to provide a 1696!
broad spectrum effect (Ofek et al., 2003; Shoaf & Hutkins, 2009). 1697!
The main goal of this research was to assess the ability of both mannan 1698!
oligosaccharides whole soluble fraction (MOS), purified mannan 1699!
oligosaccharides (pMOS), cranberry high molecular weight component (HMW) 1700!
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and the combination of MOS and HMW to inhibit adherence of C. jejuni and C. 1701!
coli to HEp-2 tissue culture cells. 1702!
 1703!
Materials and Methods 1704!
 1705!
Organisms and growth conditions. Strains of C. jejuni subsp. jejuni ATCC 1706!
29428, C. jejuni subsp. jejuni ATCC 700819, C. jejuni subsp. jejuni ATCC 33291, 1707!
C. coli ATCC 43485 and C. coli ATCC BAA-1061 were obtained from W. Miller 1708!
(Agricultural Research Service, Albany, CA) and used for all the adherence 1709!
experiments. Prior to each experiment, frozen stock cultures of each organism 1710!
were thawed, plated onto Columbia Blood Agar Base (Oxoid) with 7% of horse 1711!
blood defibrinated (BBLTM) and grown for 48 hours at 42°C in modular incubator 1712!
chamber under microaerophilic environment (5% O2, 10% CO2, and 85% N). A 1713!
single colony was inoculated into 10 ml of Brucella Broth (BBLTM; BD) 1714!
supplemented with 250 µL of Fetal Bovine Serum defined (FBS; HyClone®) and 1715!
grown in semi-solid media using the biphasic system (5 mL of Brucella agar and 1716!
10 mL of Brucella broth in sterile 25 cm2 C/N tissue culture flasks (Corning) in 1717!
horizontal position) and incubated under microaerophilic environment at 42°C 1718!
during 24 hours (late exponential phase). After 24 hours incubation, cultures 1719!
were harvested by centrifugation (4000 x g for 8 minutes). The cells were 1720!
washed twice with Phosphate-Buffered Saline (PBS) pH 7.4 and re-suspended in 1721!
Minimal Essential Medium (MEM/EBSS, HyClone, Thermo Fisher Scientific Inc, 1722!
Utah, USA) supplemented with 10% fetal bovine serum (FBS; HyClone®). MEM 1723!
was pre-equilibrated overnight at tissue culture conditions (5% CO2, 95% relative 1724!
humidity at 37°C). 1725!
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Yeast mannan oligosaccharides (MOS). Yeast mannan oligosaccharide was 1726!
obtained from Lallemand (Ontario, Canada) as a powdered material. According 1727!
to the supplier, the starting material contained 24% MOS and 25% β-glucan.  To 1728!
fractionate this material, a stock solution was prepared dissolving 100 mg of 1729!
powder per mL of distilled water. The solution was centrifuged at 1000 x g for 10 1730!
minutes to remove insoluble material. The soluble supernatant fraction was 1731!
collected, filtered through a 0.4-µm filter, and freeze dried. A stock solution was 1732!
prepared in distilled water at a final concentration of 100 mg/ml (pH 7.0). 1733!
To separate the mannan oligosaccharides from the β-glucan, the stock solution 1734!
was mixed with 100% ethanol at a ratio of 3:1. After 1 hour, two phases were 1735!
observed, allowing for separation. The precipitated β-glucan was freeze dried, 1736!
and the supernatant containing the MOS was collected and the ethanol was 1737!
removing using a rotary evaporator. The final component was then freeze dried.  1738!
 1739!
Cranberry extract. Cranberry concentrate was obtained from Ocean Spray 1740!
Cranberries, Inc (Lakeville-Middleboro, MA). The concentrate was also 1741!
fractionated by dialysis to yield a high molecular weight component (HMW). 1742!
Briefly, approximately 50 mL of concentrate was dispensed into dialysis tubing 1743!
(12,000 – 14,000 MW cutoff). The material was dialyzed for 4 days at 4°C 1744!
against distilled water with agitation. The non-dialyzable material was then freeze 1745!
dried. A stock solution was prepared by resuspending the freeze-dried material in 1746!
distilled water to a concentration of 10 mg/ml (pH 7.0). The solution was filter 1747!
sterilized using 0.45 µm filters and stored at -20°C. 1748!
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Tissue culture cells. HEp-2 cells were obtained from the American Type Culture 1749!
Collection (ATCC; Manassas, Virginia). Cells were grown in 150 cm2 sterile tissue 1750!
culture flasks (Corning) containing 50 mL of MEM with 10% Fetal Bovine Serum 1751!
(FBS) and incubated (5% CO2, 95% relative humidity at 37°C). Confluent HEp-2 1752!
cells were washed once with PBS (pH 7.4) and harvested by adding 3.5 ml of 1753!
Trypsin-EDTA Solution (Sigma) and incubating for 10 minutes at tissue culture 1754!
conditions. Then, trypsin was inactivated with 3.5 ml of FBS. After that, cells were 1755!
seeded onto 12-mm diameter wells in 24-well tissue culture plates (Thermo 1756!
Scientific) at approximately 3.6 x 105 viable cells per well, and 500 µL of Minimal 1757!
Essential Media  (MEM) supplemented with 10% FBS was added to each well. 1758!
Plates were incubated under tissue culture conditions for one day prior to the 1759!
start of each experiment. 1760!
 1761!
Adherence assays. Cells suspension of C. jejuni and C. coli were prepared as 1762!
described above. The MOS, pMOS, or HMW were mixed with bacterial cultures 1763!
(in MEM supplemented with 10% FBS and pre-incubated for 1 hour in 1764!
microaerophilic conditions at 42°C) prior to being added to the tissue culture 1765!
cells. As a control, water was added to the bacterial cultures at the same volume 1766!
as the agent. The plates were incubated for 3 hours at tissue culture conditions. 1767!
The wells were then washed 5 times with PBS (pH 7.4) to remove non-adhered 1768!
bacterial cells. Experiments were replicated 6 times (n = 6) for analysis by 1769!
quantitative plating.  Adherence was also observed microscopically (Quintero et 1770!
al., 2011) 1771!
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For other experiments, MOS and HMW were prepared as concentrated stock 1772!
solutions with distilled water at a final concentration of 100 mg/mL and 10 1773!
mg/mL. A 1:1 blend of MOS and HMW was prepared by mixing equal volumes to 1774!
give a 50 mg/mL and 5 mg/mL of each one respectively. A negative control was 1775!
prepared with distilled water and a positive control was made with the 1776!
combination of distilled water and the component at the same concentration of 1777!
the blend. The solutions were filter sterilized using 0.45-µm. 1778!
 1779!
Invasion assays. The same procedure described above was followed for cell 1780!
infection. Cell monolayers were washed 5 times with PBS (pH 7.4), and then 250 1781!
µL of pre-equilibrated MEM (supplemented with 10% FBS) with 150 µg/mL of 1782!
gentamycin sulphate (Sigma) and 250 µL of 100 mg/mL of MOS were added. 1783!
Cell monolayers were incubated 2 hours at 37°C in a 5% CO2 humidified 1784!
atmosphere chamber. Monolayer cells were then lysed with 1 mL Triton X-100 at 1785!
1% v/v in PBS (pH 7.4). Invaded bacteria were determined by serial dilutions and 1786!
cultured on plates of Brucella Agar (BBLTM; BD). The minimum inhibitory 1787!
concentration (MIC) of each agent needed to inhibit the invasion of C. jejuni and 1788!
C. coli to HEp-2 tissue cell lines were expressed as the percentage of invasive 1789!
bacterial relative to an invasion control. 1790!
 1791!
Culture Enumeration: Cells were washed as described above and detached by 1792!
addition of 0.1% Triton X-100 in PBS and repeated pipetting. The cells were 1793!
collected and enumerated on Brucella Agar (BBLTM; BD) after incubating at 42°C 1794!
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for 48 hours in microaerophilic conditions. Adherence inhibition was calculated as 1795!
the average number of adhered bacteria per ml in the control minus the average 1796!
number of adhered bacteria per ml in the treatment divided by the number of 1797!
adhered bacteria per ml in the control. 1798!
 1799!
PCR screening for adhesin identification: 1800!
Campylobacter strains were growth as described above. Cells were harvested 1801!
from Brucella broth after 24 hours of incubation and DNA was extracted using 1802!
DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany). Instructions provided 1803!
in the manufacturer’s manual for DNA extraction were followed for Gram 1804!
negative bacteria. 1805!
An internal fragment of each gene was amplified via PCR using the primers listed 1806!
in Table 1.  Genes were amplified using the following parameters: 94°C for 2 min 1807!
(1 cycle): 94°C for 45 s, 60°C (-1° per cycle) for 30 s, 70° for 1.5 min (10 cycles); 1808!
94°C for 45 s, 50°C for 30 s, and 70°C for 1.5 min (25 cycles); and 70°C for 1.5 1809!
min (25 cycles); and 70°C for 8 min (1 cycle) (Flanagan et al., 2009). PCR 1810!
amplified products (8 µL) were resolved in 1.0% agarose gel ( 60 V, 90 min) and 1811!
visualized by staining with ethidium bromide. 1812!
Table 1. Specific primers used in this study to identify presence of suspected 1813!
adhesin genes. 1814!
 1815!
 1816!
 1817!
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Locus tag Gene product Primer* Sequence 
Cj1478c 
(cadF) CadF 
cadF-F TATTTCTATGGTTTAGCAGGTGGAG  
cadF-R GCTCTACCTTCTTTAGTGTCATTGC  
Cj0628 
(capA) CapA 
capA-F TGAATCGAAGTGGAAAAATAGAAG  
capA-R CCCATTTTTGTATCTTCATAACCT  
Cj10983 
(JlpAF) JlpA 
jlpA-F TCTCAGGACTCTGGAATAAAGATTG  
jlpA-R GTGTGCTATAGTCACTAACAGGGATG  
Cj1279c 
(cadF) 
Cj1279c 
(FlpA) 
Cj1279c-F TCAGAAGATGGCAAGGTTATAGAAG  
Cj1979c-R GTTATTGCTATTGATTCAGCTGGAC  
Cj0921c 
(peb1A) PEB1 
peb1-F TCTAGGTGCTTGTGTTGCATTTAG  
peb1-R TGTCTACAGAAAACGCATCAACTC  
* Primer used to amplify a DNA fragment for the present/absent identification of 
specific adhesin gene. 
 1818!
Statistical analysis:  Significant differences between the treatments was 1819!
determined by analysis of variance (ANOVA) and Tukey’s test to compare all 1820!
pairs of columns were used to determine differences between the different 1821!
concentrations. GraphPad Prism 5 Software (Version 5.03) was used for the 1822!
statistical analysis. 1823!
 1824!
Results 1825!
Mannan oligosaccharides reduce adherence of Campylobacter jejuni and 1826!
Campylobacter coli to HEp-2 cells. Adherence assays with all strains of C. jejuni 1827!
and C. coli were conducted in the presence and absence of MOS.  Bacteria 1828!
adherence to HEp-2 cells was measured by cultural enumeration (Figure 1). The 1829!
results showed that high concentration of MOS (up to 40 mg/ml) were necessary 1830!
to achieve an anti-adherence effect of the strains used for these studies.  Thus, 1831!
40 mg/mL and 50 mg/mL inhibited adherence of C. jejuni ATCC 29428 by 94% 1832!
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and 94%, C. jejuni ATCC 700819 by 73% and 94%, C. jejuni ATCC 33291 by 1833!
71% and 82%, and C. coli ATCC 43485 by 91% and 92%, respectively.  1834!
However, there was no significant effect on the adherence of C. coli ATCC BAA- 1835!
1061, suggesting that the effect found in MOS may be Campylobacter strain- 1836!
specific. Microscopic observations provided qualitative evidence of the anti- 1837!
adherence activities of the MOS (Figure 2). 1838!
 1839!
Adherence of C. jejuni and C. coli in the presence and absence of purified MOS 1840!
gave similar results as for the whole soluble MOS (Figure 3). Experiments 1841!
revealed that the minimum inhibitory concentration of the purified MOS was also 1842!
40 mg/mL and that adherence of C. coli ATCC BAA-1061, was not affected by 1843!
MOS at any of the concentrations. 1844!
 1845!
Mannan oligosaccharides does not reduce invasion of Campylobacter jejuni 1846!
and Campylobacter coli to HEp-2 cells. Invasion assays were conducted for all 1847!
five strains of Campylobacter on HEp-2 cells. Invasion was measured by cultural 1848!
enumeration. The results revealed that there were no significant reductions in the 1849!
invasion of C. jejuni ATCC 700819, C. jejuni ATCC 33291, C. jejuni ATCC 1850!
29428, C. coli ATCC 43485 and C. coli ATCC BAA-1061 in presence of MOS (50 1851!
mg/mL) (data not shown). 1852!
 1853!
High Molecular weight of cranberry extract reduces adherence of 1854!
Campylobacter jejuni and Campylobacter coli to HEp-2 cells. Adherence assays 1855!
with all five strains of C. jejuni and C. coli were conducted in the presence and 1856!
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absence of cranberry HMW component to HEp-2 cells. Adherence was 1857!
measured by cultural enumeration (Figure 4). The results revealed that the 1858!
adherence of C. jejuni strains was inhibited by greater than 90% at the highest 1859!
concentration of 5 mg/mL of HMW. However, the minimum concentration to 1860!
achieve more than 50% of inhibition for four of five of the strains tested was 3 1861!
mg/mL. There was no significant effect in the adherence of C. coli ATCC BAA- 1862!
1061. 1863!
 1864!
High Molecular weight of cranberry extract does not reduce invasion of 1865!
Campylobacter jejuni and Campylobacter coli to HEp-2 cells. Invasion assays of 1866!
C. jejuni and C. coli in presence and absence of cranberry HMW component 1867!
were measured by numerical enumeration (data no shown). The results revealed 1868!
that there was no effect in the invasion process in presence of the highest dose 5 1869!
mg/mL of HMW with all the strains tested in this study.  1870!
 1871!
Combinations of MOS and HMW are not additive. Adherence assays with all 1872!
five strains of C. jejuni and C. coli were conducted in the presence and absence 1873!
of a blend (1:1) of cranberry HMW and MOS. Bacteria adherence to HEp-2 cells 1874!
was measured by cultural enumeration (Figure 5). Although, both HMW and 1875!
MOS were effective at reducing adherence of C. jejuni ATCC 700819, C. jejuni 1876!
ATCC 33291 and C. jejuni ATCC 29428 to HEp-2 cells, the results revealed that 1877!
there was not additive effect of the blend HMW/MOS. That is, the extent of the 1878!
inhibition was neither additive nor augmented by the mixture of the HMW/MOS. 1879!
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Results with C. coli ATCC 43485 showed as before that MOS is effective 1880!
against the adherence to HEp-2 cells, but HMW was not.  There was no 1881!
significant effect on the adherence of C. coli ATCC BAA-1061, suggesting that 1882!
the effect found in MOS and HMW may be Campylobacter strain-specific. 1883!
 1884!
Campylobacter jejuni expresses all of the adhesins screened in this study. 1885!
PCR was conducted to amplify adhesin genes using specific primers (Table 2). 1886!
All C. jejuni strains were positive for the presence of all five adhesins tested in 1887!
this study. However, only two adhesin genes were identified for C. coli strains.  1888!
 1889!
Table 2. Presence/Absence of adhesin genes for the Campylobacter strains used 1890!
in this study.  1891!
 Target Adhesin genes 
Strains cadF peb1A jlpA capA Cj1279 
C. coli ATCC BAA-1061 + + - - - 
C. coli ATCC 43485 + + - - - 
C. jejuni ATCC 700819 + + + + + 
C. jejuni ATCC  33291 + + + + + 
C. jejuni ATCC 29428 + + + + + 
(+ Presence / -  Absence) 1892!
 1893!
Discussion 1894!
 1895!
Over the past several years, different beneficial effects have been 1896!
attributed to MOS (Davis et al., 2002; Ferket et al., 2005; Hanning et al., 2009; 1897!
Staykov et al., 2007). Because they are also easy to produce at a relatively low 1898!
cost, MOS have gained significant interest in agricultural applications. In 1899!
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particular, MOS have been widely used in animal production as a feed 1900!
supplement to replace antibiotics and other growth promoting agents (Baurhoo et 1901!
al., 2009; Castillo et al., 2008). Most studies have been conducted in-vivo with 1902!
broiler chicks, pigs, and fish and less extended in cattle and pets. In these 1903!
reports, the population of pathogenic bacteria such as Salmonella, E. coli, 1904!
Campylobacter and Clostridium was reduced after supplementation with MOS in 1905!
the animal diet. Additionally, MOS have been shown to enhance growth 1906!
performance of livestock animals.  1907!
Cranberry is a widely consumed fruit in United States and it has been 1908!
identified to have a diverse biological properties (Duarte et al., 2006; Ofek et al., 1909!
1991; Sobota, 1984), among them the ability to inhibit the adherence and biofilm 1910!
formation of some pathogens to epithelial cells (Burger et al., 2000; Foo et al., 1911!
2000; Zafriri et al., 1989). A high molecular weight component isolated from 1912!
cranberry has been found to present the anti-adherent capacity (Burger et al., 1913!
2000), acting as inhibitor or by altering bacterial surface hydrophobicity 1914!
(Steinberg et al., 2005) 1915!
In this study, adherence inhibition of three strains of C. jejuni and two 1916!
strains of C. coli to HEp-2 cells in the presence of MOS, pMOS, cranberry HMW 1917!
and a blend of MOS/HMW was determined. The results showed that both 1918!
fractions MOS and pMOS at 40 mg/ml and 50 mg/mL have the property to inhibit 1919!
adherence of some strains of Campylobacter. However, there were no significant 1920!
differences between the whole soluble mannan oligosaccharide and purified 1921!
fractions. This suggests that the anti-adherence effect is due to the mannan 1922!
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oligosaccharides fraction and that the β-glucan fraction does not inhibit 1923!
adherence. The mannan oligosaccharides material used in this study is derived 1924!
from yeast cell walls produced from S. cerevisiae and was composed mainly by 1925!
mannan oligosaccharides, β-glucan and others unknown ingredients. However, 1926!
the exact amount of mannan oligosaccharides in both fractions (MOS and 1927!
pMOS) is unknown. Efforts to understanding and identifing the mode of action of 1928!
each of the commercial MOS compounds is worthy of exploration. 1929!
Results shown that the adherence of C. jejuni strains and C. coli ATCC 1930!
43485 was significantly reduced by cranberry HMW at a minimum concentration 1931!
of 2 mg/mL and 3 mg/mL, respectively. However, at higher concentrations (up to 1932!
5 mg/mL) further reductions in adherence were not observed. Adherence of C. 1933!
coli ATCC BAA-1061 was not inhibited by any dose of HMW.  1934!
The results with the blend of MOS/HMW showed that there was not an 1935!
additive effect with these components. This suggests that some of the strains 1936!
used in this study express a particular adhesin that is target for both MOS and 1937!
HMW, or one of the anti-adhesive agents have a broad spectrum to target 1938!
different Campylobacter adhesins.  1939!
Although the adherence mechanisms of Campylobacter are not well 1940!
understood, several adhesins have been described. Importantly, adherence to 1941!
host epithelial cells appears to be crucial for C. jejuni colonization of chickens 1942!
(Flanagan et al., 2009; Ziprin et al., 1999). Adhesins as CadF (Campylobacter 1943!
adhesin to fibronection) are involved in the adherence of C. jejuni to fibronection 1944!
(Konkel et al., 1999). Previous studies have suggested that CadF promotes 1945!
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adherence in cell culture systems and during chicken colonization (Mourik, 2011: 1946!
Flanagan, 2009; Konkel et al, 1997). Moreover, C. jejuni cadF mutants were 1947!
shown to have reduced adherence (50%) to intestinal human cells compared 1948!
with the C. jejuni wild-type strain (Flanagan et al., 2009; Monteville, Yoon, & 1949!
Konkel, 2003). Two other major outer membrane proteins, CapA (Campylobacter 1950!
adhesin protein A) and JIlpA (Campylobacter jejuni surface lipoprotein A) have 1951!
been identified and suggested to mediate adherence of the bacterium to 1952!
epithelial cells (Flanagan et al., 2009; Jin, Song et al., 2003). However, Flanagan 1953!
et al, (2009) reported that CapA is not conserved among the strains of C. jejuni 1954!
tested in the study, suggesting this adhesin may not be essential for 1955!
Campylobacter colonization in chickens. Nevertheless, this particular protein may 1956!
contribute during the initial steps of the adherence process. Jin et al, (2003) 1957!
reported that JlpA is a surface exposed lipoprotein that is crucial for HEp-2 cell 1958!
binding. Previous work has suggested that JlpA is located predominately in the 1959!
bacterial inner membrane and can be found loosely associated with the outer 1960!
membrane (Flanagan et al, 2009). PEP1 is a periplasmic binding protein 1961!
associated with ABC transports (ATP-binding cassette (ABC) transports). 1962!
Disruption of peb1A has been shown to reduce C. jejuni adherence to human 1963!
HeLa epithelial cells (Kervella et al, 1993), and C. jejuni mutant strains failed to 1964!
colonize the intestinal tract of mice (Pei et al, 1998). There are still open 1965!
questions to be resolved about Campylobacter pathogenesis.  In particular, it will 1966!
be necessary to understand the importance and contribution of each known 1967!
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adhesin for colonization, and additionally to identify the specific receptors for 1968!
these adhesins. 1969!
 There are few in vitro studies that have compared MOS preparations in an 1970!
anti-adherence model. Previously, in vitro analysis with yeast-derived 1971!
mannoproteins suggested that the yeast cell wall is effective at inhibiting 1972!
adherence of C. jejuni to Caco-2 cells, but it had no significant effect on invasion 1973!
(Ganan et al., 2009). Mannose derived from Candida albicans cell walls was 1974!
shown by Oyofo et al., (1989) to inhibit the in vitro adherence of Salmonella 1975!
typhimurium to intestinal cells of day old chickens. Another study reported that 1976!
mannose was effective at blocking adherence of C. jejuni on Caco-2 cells by 1977!
(Russell & Blake, 1994). These results indicated that the mannose content in the 1978!
mannoprotein fraction appeared to be crucial for inhibiting the adherence process 1979!
of some pathogenic microorganisms. 1980!
Mannose is a component of N-glycan structures (Parry et al., 2006), and 1981!
many pathogens bacteria bind to mannose residues on the host tissue. Most of 1982!
the mannose-binding lectins that have been identified in bacteria contain FimH- 1983!
like adhesins commonly located at the tip of type I fimbriae (Firon et al., 1984; 1984!
Ganner & Schatzmayr, 2012).  However, these extracellular adhesins have not 1985!
been recognized in C. jejuni. In contrast, E. coli and Salmonella are known to 1986!
possess these mannose-sensitive type 1 fimbriae (Day et al., 2009; Firon et al., 1987!
1984; Neeser et al., 1986). In a previous study, Day et al. (2009) reported that C. 1988!
jejuni 11168-O has a mannose-binding lectic whose expression was dependent 1989!
on the environmental temperature and atmospheric conditons. Aditionally, Day et 1990!
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al. (2009) suggested that mannose recognition by C. jejuni may not require 1991!
mannose for initial adherence to host tissues, but may be unnecessary for 1992!
subsquent colonisation (Thomas et al., 2004; Thomas et al., 2002).  1993!
Finally, it was previously reported that C. jejuni does not ferment or 1994!
oxidase carbohydrates as a carbon source (Weingarten et al., 2009).  Therefore, 1995!
any observed reduction of binding can be attributed to direct interactions involved 1996!
in adherence and not as an indirect metabolic effect (Day et al., 2009).  1997!
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Figure 1. Adherence of C. jejuni and C. coli to HEp-2 cells in the presence of 2218!
mannan oligosaccharides (0, 10, 20, 30, 40 and 50 mg/mL) analyzed by cultural 2219!
enumeration (n=6). Statistically significant effects are indicated by an asterisk. 2220!
 2221!
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Figure 2. Microscopy observation 1000 x magnification of C. coli ATCC 43485 2248!
adhere to surface of HEp-2 cells. Control (A) and 50 mg/mL of MOS (B). 2249!
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Figure 3. Adherence of C. jejuni and C. coli to HEp-2 cells in the presence of 2284!
purified mannan oligosaccharides (0, 10, 20, 30, 40 and 50 mg/mL) analyzed by 2285!
cultural enumeration (n=6). Statistically significant effects are indicated by an 2286!
asterisk. 2287!
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Figure 4. Adherence of C. jejuni and C. coli to HEp-2 cells in the presence of high 2318!
molecular weigh of cranberry extract (0, 1,2,3,4 and 5 mg/mL) analyzed by 2319!
cultural enumeration (n=6). Statistically significant effects are indicated by an 2320!
asterisk. 2321!
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Figure 5. Adherence of C. jejuni and C. coli to HEp-2 cells in the presence of high 2363!
molecular weight of cranberry extract and yeast mannan oligosaccharides (1:1, 2364!
HMW 5 mg/mL, MOS 50 mg/mL) analyzed by cultural enumeration (n=6). 2365!
Statistically significant effects are indicated by an asterisk, the letters significant 2366!
the differences among the treatments. 2367!
 2368!
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Adherence inhibition of Campylobacter jejuni and Campylobacter coli to HEp-
2 cells by pectin oligosaccharides 
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Abstract 
 
Many recent studies have described the beneficial effects and mechanisms of 
action of prebiotics. However, there is now active interest in prebiotic 
oligosaccharides derived from suitable bioresources. Pectic oligosaccharides 
(POS) are non-digestible oligosaccharides commonly found in fruit and 
vegetables. POS have been recognized for their potential prebiotic properties. In 
addition to their ability to modulate the gut microbiota, POS have also been 
suggested to inhibit attachment of some pathogens to epithelial cells. The goal of 
this research was to assess the ability of orange pectic oligosaccharides to inhibit 
the adherence of C. jejuni ATCC 29428, C. jejuni ATCC 33291, C. jejuni ATCC 
700819, C. coli ATCC 43485 and C. coli ATCC BAA-1061. Adherence 
experiments were performed using a human epithelial tissue cell line (HEp-2) in 
the absence or presence of POS. There were no significant reductions in 
adherence of any Campylobacter strains. However, adherence tended to 
increase as the concentration of POS increases. The results obtained in this 
work suggest that POS does not have an anti-adhesive effect on the specific 
strains of C. jejuni and C. coli tested in this study. Further investigation is 
necessary to determine the mechanisms of interaction of POS and 
Campylobacter strains in an in vitro model. 
 
Introduction 
 
Prebiotics are defined as non-digestible food ingredients that beneficially 
affect the host by selectively stimulating the growth and/or activity of one or 
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limited number of bacterial species in the colon (Gibson et al., 1995). The 
commercial prebiotic products currently on the market are produced by 
enzymatic synthesis or degradation of materials such as lactose, sucrose, inulin, 
starch and xylan (Hotchkiss et al., 2003; Crittenden & Playner, 1996). 
Non-digestible oligosaccharides (NDO) have been suggested as potential 
agents for improving gut health and well-being by maintaining a balanced 
intestinal microbiota (Roberfroid, 2007). Recently, some NDO have been 
recognized to have other biological properties.  Specifically, they may block the 
adherence of some pathogenic bacteria, preventing these pathogens from 
attaching to target cells in the gut (Shoaf et al., 2006).  Since adherence is the 
first and more important step in bacteria pathogenesis (Savage, 1977; Shoaf & 
Hutkins, 2009), strategies based adherence inhibition could be very effective. 
NDOs are among the agents being considered for this function (Klemm et al., 
2010; Shoaf et al., 2006).  Specifically, pectic oligosaccharides (POS) have been 
proposed to have this activity (Paeschke & Aimutis, 2011).  
Pectin is an acidic polysaccharide found in fruit and vegetable processing 
residues (Poli et al., 2011). Pectin consists of homogalacturonan and 
rhamnogalacturonan I (RGI) in the backbone with arabinan, galactan and 
arabinogalactan neutral sugar-chains attached to rhamnose in RGI regions 
(Carpita & Gibeaut, 1993; Holck et al., 2014; Ridley et al., 2001). POS are 
complex polysaccharides that represent one of the major components of plant 
cell wall of dicotyledonous plants (Mandalari et al., 2006; Willats et al., 2000). 
POS are formed via enzymatic hydrolysis of pectins (DP 2-20) (Holck et al., 
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2014), resulting mainly in monomers of α-1-4-linked galactosyluronic acid 
residues (Alonso & Parajo, 2010).  
Pectin-derived oligosaccharides from plant cell walls are produced by 
several chemical and physical steps.  The cell wall material is pre-treated and the 
pectin polysaccharides are extracted.  The oligosaccharides are released and 
separated and then purified by chromatography (Holck et al., 2014). Commercial 
pectin for food additive purposes depends of molecular weight, degree of 
esterification and intrinsic viscosity (Hotchkiss et al., 2003). 
POS have been proposed to be a potential prebiotic (Ganan et al., 2010). 
POS have been evaluated to stimulate the growth of beneficial bacteria, including 
Lactobacillus (Mandalari et al., 2006b) and Bifidobacterium (Manderson et al., 
2005; Olano-Martin et al., 2002). In addition to their putative prebiotic activity, 
POS have also been recognized for their ability to inhibit the adherence of 
pathogens (Hotchkiss et al., 2003; Holck et al., 2014).  
The main goal of this research, therefore, was to asses the ability of pectic 
oligosaccharides (POS) to inhibit the adherence of C. jejuni and C. coli in HEp-2 
tissue culture cells.. 
 
Materials and Methods 
 
Organisms and growth conditions. Strains of C. jejuni subsp. jejuni ATCC 
29428, C. jejuni subsp. jejuni ATCC 700819, C. jejuni subsp. jejuni ATCC 33291, 
C. coli ATCC 43485 and C. coli ATCC BAA-1061 were obtained from W. Miller 
(Agricultural Research Service, Albany, CA) and used for all the adherence 
experiments. Prior to each experiment, frozen stock cultures of each organism 
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were thawed, plated onto Columbia Blood Agar Base (Oxoid) with 7% of Horse 
Blood defibrinated (BBLTM) and grown for 48 hours at 42°C in modular incubator 
chamber under microaerophilic environment (5% O2, 10% CO2, and 85% N). A 
single colony was inoculated into 10 ml of Brucella Broth (BBLTM; BD) 
supplemented with 250 µL of Fetal Bovine Serum (FBS; HyClone®) and grown in 
semi-solid media using the biphasic system (5 mL of Brucella agar and 10 mL of 
Brucella broth in sterile 25 cm2 C/N tissue culture flasks (Corning) in horizontal 
position) and incubated under microaerophilic environment at 42°C during 24 
hours (late exponential phase). After 24 hours incubation, cultures were 
harvested by centrifugation (4000 x g for 8 minutes). The cells were washed 
twice with Phosphate-Buffered Saline (PBS) pH 7.4 and re-suspended in Minimal 
Essential Medium (MEM/EBSS, HyClone, Thermo Fisher Scientific Inc, Utah, 
USA) supplemented with 10% fetal bovine serum (FBS; HyClone®). MEM was 
pre-equilibrated overnight at tissue culture conditions (5% CO2, 95% relative 
humidity at 37°C). 
 
Orange pectic oligosaccharide (POS): Citric pectic oligosaccharide was 
obtained from Agricultural Research Service Eastern Regional Research Center 
(Wyndoor, PA), as a powdered material. A stock solution of 10 mg/ml was 
prepared in phosphate buffer solution (PBS) at pH 7.4, filtered through a 0.45µm 
filter and stored at -20°C. 
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Tissue culture cells. HEp-2 cells were obtained from the American Type Culture 
Collection (ATCC; Manassas, Virginia). Cells were grown in 150 cm2 sterile tissue 
culture flasks (Corning) containing 50 mL of MEM with 10% Fetal Bovine Serum 
(FBS) and incubated (5% CO2, 95% relative humidity at 37°C). Confluent HEp-2 
cells were washed once with PBS (pH 7.4) and harvested by adding 3.5 ml of 
Trypsin-EDTA Solution (Sigma) and incubating for 10 minutes at tissue culture 
conditions. Then, trypsin was inactivated with 3.5 ml of FBS. After that, cells were 
seeded onto 12-mm diameter wells in 24-well tissue culture plates (Thermo 
Scientific) at approximately 3.6 x 105 viable cells per well, and 500 µL of Minimal 
Essential Media  (MEM) supplemented with 10% FBS was added to each well. 
Plates were incubated under tissue culture conditions for one day prior to the 
start of each experiment. 
 
Adherence assays. Cells suspension of C. jejuni and C. coli were prepared as 
described above.  The POS were mixed with bacterial cultures (in MEM 
supplemented with 10% FBS and pre-incubated for 1 hour in microaerophilic 
conditions at 42°C) prior to addition to the tissue culture cells. As a control, water 
was added to the bacterial cultures at the same volume as the agent. The plates 
were incubated for 3 hours at tissue culture conditions. The wells were then 
washed 5 times with PBS (pH 7.4) to remove non-adhered bacterial cells. 
Experiments were replicated 6 times (n = 6) for analysis by quantitative plating.  
Adherence was also observed microscopically (Quintero et al., 2011). 
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Invasion assays. The same procedure described above was followed for cell 
infection. Cell monolayers were washed 5 times with PBS (pH 7.4), and then 250 
µL of pre-equilibrated MEM (supplemented 10% FBS) with 150 µg/mL of 
gentamycin sulphate (Sigma) and 250 µL of 10 mg/mL of POS were added. Cell 
monolayers were incubated 2 hours at 37°C in a 5% CO2 humidified atmosphere 
chamber. Monolayer cells were then lysed with 1 mL Triton X-100 at 1% v/v in 
PBS (pH 7.4). Invaded bacteria were determined by serial dilutions and cultured 
on plates of Brucella Agar (BBLTM; BD). The minimum inhibitory concentration 
(MIC) of each agent needed to inhibit the invasion of C. jejuni and C. coli to HEp-
2 tissue cell lines were expressed as the percentage of invasive bacterial relative 
to an invasion control. 
 
Culture enumeration: Cells were washed as described above and detached by 
addition of 0.1% Triton X-100 and repeated pipetting. The cells were collected 
and enumerated on Brucella Agar (BBLTM; BD) after incubating at 42°C for 48 
hours in microaerophilic conditions. Adherence inhibition was calculated as the 
average number of adhered bacteria per ml in the control minus the average 
number of adhered bacteria per ml in the treatment divided by the number of 
adhered bacteria per ml in the control. 
 
Statistical analysis:  Significant differences between the treatments were 
determined by analysis of variance (ANOVA) and Tukey’s test to compare all 
pairs of columns were used to determine differences between the different 
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concentrations. GraphPad Prism 5 Software (Version 5.03) was used for the 
statistical analysis. 
 
Results 
 
Pectic oligosaccharides do not reduce adherence of Campylobacter jejuni 
and Campylobacter coli to HEp-2 cells.  Adherence of C. jejuni and C. coli in 
presence and absence of pectic oligosaccharides to HEp-2 cells was measured 
by cultural enumeration (Figure 1). The results revealed that POS did not inhibit 
the adherence of all five strains of Campylobacter tested in this study (Figure 2). 
Interestingly, adherence tended to increase as the POS concentration increases. 
We suggest that POS might function as a bridge to enhance binding of some 
strains of Campylobacter to epithelial cells. However, C. jejuni ATCC 33291 was 
the only strain that showed adherence reduction but it was not statistically 
significant compared with the control. 
 
Pectic oligosaccharides does not reduce invasion of Campylobacter jejuni 
and Campylobacter coli to HEp-2 cells. Invasion assays of C. jejuni and C. coli 
were conducted in presence and absence of POS by numerical enumeration 
(Figure 3). The results revealed that there was no inhibitory effect on invasion in 
the presence of the highest dose 5 mg/mL of POS of all the strains to HEp-2 
cells. 
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Discussion 
 
The anti-adherence strategy against pathogens was proposed several 
years ago (Andersson et al., 1986; Cravioto et al., 1991; Ofek & Beachey, 1978). 
Since then, many studies have evaluated the activity of several oligosaccharides 
that may act as molecular decoys and block the bacterial attachment to epithelial 
cells. Prebiotic oligosaccharides are of considerable interest because, in addition 
to their health promoting properties, they have been suggested to inhibit the 
adherence of some pathogens and reduce bacterial colonization and infection. 
Oligosaccharides from pectin (POS) are proposed to be in the group of potential 
new generation of prebiotics (Paeschke & Aimutis, 2011). 
In this report, we compared the ability of pectin oligosaccharides to inhibit 
the adherence of C. jejuni and C. coli to HEp-2 cells. The results showed that 
POS had no effect on adherence or the invasion of any of the Campylobacter 
strains tested in this study.  Adherence to HEp-2 was increased in some strains. 
Pectic oligosaccharides are a co-product of pectin manufacturing.  They 
are a significant component of the supernatant remaining after pectin 
precipitation (Ganan et al., 2010). Therefore, pectin is a suitable raw material for 
the production of oligosaccharides with promising prebiotic potential (Alonso & 
Parajo, 2010). The most common commercial sources of POS are citrus peel, 
apple pomace, sugar beet pulp and potatoes pump (Holck et al., 2014). 
Specially, orange pectin oligosaccharides were shown to prevent adhesion of 
several E. coli strains, including E. coli NTCC 12900, E. coli NTCC 13127, E. coli 
NTCC 13128, E.coli NTCC O111:H27, and Desulfovibrio desuldurincans. 
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Adherence inhibition of over 80% of inhibition were reported (Rhoades et al., 
2008) and invasion of C. jejuni in Caco-2 cells (Ganan et al., 2010; Olano-Martin 
et al., 2003). POS, have also shown protective effects against E. coli 
verocytototixins in HT29 tissue culture cells (Olano-Martin et al., 2003; Paeschke 
& Aimutis, 2011). Guggenbichler et al., 1997 reported that digalacturonic acid (α-
D-GalpA-(1-4)-D-GalpA) derived from acid pectin oligosaccharides inhibited 
adherence of P-fimbriated E. coli to uroepithelial cells.  
The methyl-esterified oligogalacturonic acids component in POS appear to 
be responsible for the anti-adherent property and anti-toxin attachment to specific 
epithelial receptors (Holck et al., 2014; Rhoades et al., 2008). However, it is clear 
that the effect of POS may be strain specific. 
Holck et al., 2014 reported that differences in POS sources and 
composition could alter the results of bacterial adherence and invasion to specific 
epithelial cells. Thus, a better understanding of the POS structure, function and 
relationship with bacterial pathogens is required. 
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Figure 1. Adherence of C. jejuni and C. coli to HEp-2 cells in the presence of 
Pectic Oligosaccharide (0, 1, 2, 3, 4 and 5 mg/mL) analyzed by cultural 
enumeration (n=6). An asterisk indicates statistically significant effects. 
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Figure 2. Microscopy observation 1000 x magnification of C. coli ATCC 43485 
adhere to surface of HEp-2 cells. Control (A) and 5 mg/mL of POS (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! 115!
!
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
! 116!
!
Figure 3. Invasion of C. jejuni and C. coli to HEp-2 cells in the presence of POS 5 
mg/mL) analyzed by cultural enumeration (n=6). Statistically significant effects 
are indicated by an asterisk. 
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Chapter 5 
 
Conclusion 
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In this research we proposed that mannan oligosaccharides and cranberry high 
molecular weight components could be used to inhibit adherence of C. jejuni and 
C. coli strains to epithelial cells. Specifically, we established that a mannan 
oligosaccharides fraction was responsible for the anti-adherent effect against the 
Campylobacter strains used in this studied. Furthermore, it was determined that 
pectic oligosaccharides derived from orange did not inhibit the adherence of C. 
jejuni and C. coli strains to epithelial cells. The major findings of this research are 
described below. 
 
• MOS and pMOS effectively reduce adherence of C. jejuni and C. coli 
strains in tissue culture experiments. 
• MOS are not effective at reducing the invasion of C. jejuni and C. coli 
strains to epithelial cells. 
• The minimum MOS and pMOS concentration required for C. jejuni and C. 
coli strains adherence inhibition was 40 mg/mL; higher concentrations did 
not exhibit significantly higher adherence inhibition. 
• The activity of the effective MOS was attributed to the mannan fraction 
and not to the β-glucan fraction.  
• Cranberry high molecular weigh component effectively reduce the 
adherence of C. jejuni and C. coli strains in tissue culture experiments. 
• Cranberry high molecular weigh component is not effective for reducing 
invasion of C. jejuni and C. coli strains to epithelial cells. 
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• The minimum HMW concentration required for inhibiting adherence of C. 
jejuni and C. coli was 2 and 3 mg/mL, respectively; however, higher 
concentrations did not enhance adherence inhibition. 
• There was no additive effect observed by using a combination of MOS 
and HMW against adherence of C. jejuni and C. coli strains to epithelial 
cells. 
• The anti-adherence effect of MOS and HMW was strain-specific. 
• Pectin oligosaccharides did not inhibit adherence or invasion of C. jejuni 
and C. coli strains. 
• Collectively, the results obtained from this study provide evidence that 
mannan oligosaccharides and cranberry extract have anti-adherence 
activity and may be useful act as prophylactic agents against pathogenic 
bacteria that infect production animals. 
